🏷

Classifications

Harrison's Part

Mechanistic Nosology

👪

Inheritance

1

Autosomal recessive HP:0000007

The disease is inherited in an autosomal recessive manner. Reported families carry homozygous variants (consanguineous unions) or compound heterozygous variants in UCHL1, cosegregating with the phenotype. Heterozygous UCHL1 loss-of-function is a distinct, later-onset autosomal dominant disorder (SPG79A) rather than a carrier state for this entity — see `notes`.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"a previously undescribed homozygous missense mutation within the ubiquitin "

The index family comprised three affected siblings from a consanguineous union sharing a homozygous UCHL1 missense variant — the classic recessive architecture.

PMID:29735986 SUPPORT Human Clinical

"Spastic Paraplegia-79 (SPG79) is an autosomal recessive type of childhood onset "

Independently states the autosomal recessive, childhood-onset nature of SPG79.

◈

Mechanistic Hypotheses

1

Neurodegeneration results from departure from an optimal window of UCH-L1 activity in either direction, not simply from reduced hydrolase activity

uchl1_activity_window EMERGING

Evidence balance 5 support

The p.Glu7Ala, p.Ala216Asp, splice-site and in-frame-deletion alleles all reduce UCH-L1 function, which supports a straightforward loss-of-function model. The p.Arg178Gln allele, however, has roughly four-fold increased hydrolytic activity in vitro, and later biophysical work confirmed a genuine kcat gain with a more reactive catalytic cysteine. Two non-exclusive reconciliations are on the table: (i) that the unifying lesion is reduced steady-state UCH-L1 protein rather than specific activity, consistent with the roughly four-fold lower total UCHL1 measured in patient fibroblasts; and (ii) that both hypoactive and hyperactive enzyme perturb ubiquitin homeostasis, implying an optimal activity window. The original authors additionally propose that the increased activity of p.Arg178Gln may be protective for cognition, which is remarkably preserved in those patients. A third, independent line of evidence pushes in the same direction: a catalytically dead UCHL1 C90A knock-in mouse does NOT reproduce the sensory/motor deficits, gracile-tract degeneration or premature death of UCHL1-deficient mice, implying that loss of hydrolase activity alone is not sufficient for the neurodegenerative phenotype and that non-hydrolase UCH-L1 functions (ubiquitin stabilisation, ubiquitin ligation, cytoskeletal interaction) matter. Which model is correct is unresolved.

Show evidence (5 references)

PMID:28007905 SUPPORT In Vitro

"identified missense variants reveal surprisingly different functional "

States directly that the two disease alleles in one patient have opposite functional consequences — the observation the hypothesis is built on.

PMID:28007905 SUPPORT Human Clinical

"activity of the Arg178Gln variant offers a protective effect on cognitive "

The authors' own proposed reconciliation — increased activity as cognitively protective.

PMID:38185323 SUPPORT In Vitro

"showed higher catalytic activity than "

Independently confirms and structurally explains the gain of catalytic activity in the p.Arg178Gln disease allele.

+ 2 more references

?

Discussions and Knowledge Gaps

1

Does the dying-back axonal degeneration with terminal spheroid formation documented in the Uchl1-mutant gad mouse actually describe the neuropathology of human biallelic UCHL1 disease, and are Purkinje cells the principal cerebellar target in patients?

HUMAN MODEL MISMATCH OPEN uchl1_human_neuropathology_gap

Attached to

pathophysiology#Dying-Back Axonal Degeneration pathophysiology#Cerebellar Degeneration

The cellular mechanism curated here — dying-back axonopathy, terminal spheroids, retrograde ubiquitin-positive deposits, monoubiquitin depletion — rests almost entirely on the gad mouse. No human post-mortem neuropathological series of biallelic UCHL1 disease is available, and the very small number of reported families means the cellular lesion in patients is inferred rather than observed. The cerebellar node is additionally inferred from the conserved Purkinje-degeneration module rather than from UCHL1-specific human tissue. The mismatch matters because it is the mechanistic link from a proteostasis defect to selective long-tract vulnerability, and because mouse Uchl1 loss is partly compensated by Uch-L3, a redundancy whose human equivalence is unknown.

Proposed experiments

Human neuropathological characterisation of biallelic UCHL1 disease

exp_uchl1_human_neuropathology

Post-mortem examination of optic nerve, cerebellum, dorsal columns and corticospinal tracts in biallelic UCHL1 patients, assessing axonal spheroids, ubiquitin-conjugate accumulation, free-monoubiquitin levels and Purkinje-cell counts against age-matched controls.

Patient iPSC-derived neuron modelling

exp_uchl1_ipsc_neurons

Generate iPSC-derived retinal ganglion cells, cortical projection neurons and cerebellar neurons from patients carrying each allele class (p.Glu7Ala hypoactive, p.Arg178Gln hyperactive, null), and measure free-ubiquitin pool, ubiquitin-conjugate accumulation, axonal transport and distal-axon integrity to test the activity-window hypothesis in human cells.

Show evidence (2 references)

PMID:10471497 SUPPORT Model Organism

"the mutant is characterized by 'dying-back' type axonal "

The mouse-only cellular pathology that is the basis of the open translational question.

PMID:11555633 SUPPORT Model Organism

"To assess whether the two hydrolases have redundant function, we generated mice "

The Uch-L1/Uch-L3 double-mutant experiment probes functional redundancy among UCH isozymes in mouse, a confounder for translating the model to human disease.

⚙

Pathophysiology

8

Biallelic UCHL1 Loss of Function

UCHL1 encodes ubiquitin C-terminal hydrolase L1, a neuron-specific (and testis/ovary-expressed) cysteine-protease deubiquitinating enzyme that is among the most abundant proteins in the brain. Reported disease alleles compromise the enzyme in several distinct ways: the index p.Glu7Ala allele lies in the ubiquitin-binding region and causes a >7-fold loss of ubiquitin affinity with near complete loss of hydrolase activity (>100-fold reduction in catalytic efficiency); p.Ala216Asp renders the protein insoluble (loss of function); a canonical splice-site variant (c.459+2T>C) and an in-frame deletion (p.Gly210del) have also been reported. Notably one allele, p.Arg178Gln, paradoxically increases hydrolytic turnover, so the unifying lesion is loss of normal UCH-L1 function/steady-state protein rather than strictly reduced catalysis (see `mechanistic_hypotheses`).

UCHL1 hgnc:12513

cysteine-type deubiquitinase activity GO:0004843 ↓ DECREASED ubiquitin binding GO:0043130 ↓ DECREASED

Downstream

Failure of Neuronal Ubiquitin Recycling Loss of UCH-L1 hydrolase and ubiquitin-binding function directly impairs the processing and recycling of ubiquitin in neurons.

Show evidence (5 references)

PMID:23359680 SUPPORT In Vitro

"In vitro, the mutation led to a near complete loss of UCHL1 hydrolase activity. "

Directly demonstrates that the disease allele abolishes UCH-L1 hydrolase activity.

PMID:27515257 SUPPORT Other

"UCH-L1 is not essential for neuronal development but it is absolutely required for the maintenance of axonal integrity"

Explains the natural history: UCH-L1 is dispensable for neuronal development — hence the normal early development of affected children — but is absolutely required for maintenance of axonal integrity thereafter, which is why the disease is degenerative rather than malformative.

PMID:27515257 SUPPORT Other

"it is estimated to make up 1-5% of total neuronal protein"

Quantifies the extraordinary neuronal abundance of UCH-L1, which underlies why its loss is tolerated poorly and specifically by neurons.

+ 2 more references

Failure of Neuronal Ubiquitin Recycling

UCH-L1 binds monoubiquitin with high avidity, prolongs its half-life and generates free monomeric ubiquitin from adducts and precursors. Loss of UCH-L1 function therefore depletes the neuronal free-monoubiquitin pool on which all downstream ubiquitin conjugation depends. This was shown in vivo in the gad mouse, in which UCH-L1 function is lost and neuronal monoubiquitin is reduced.

ubiquitin recycling GO:0010992 ↓ DECREASED protein deubiquitination GO:0016579 ↓ DECREASED

Downstream

Impaired Ubiquitin-Dependent Protein Turnover A depleted free-ubiquitin pool limits substrate ubiquitination and hence flux through the ubiquitin-proteasome degradation system.

Show evidence (2 references)

PMID:12913066 SUPPORT Model Organism

"The gad mouse, in which the function of UCH L1 is lost, exhibited a reduced "

Establishes in vivo that loss of UCH-L1 function reduces the neuronal monoubiquitin level. Model-organism evidence for the molecular step, not for the human phenotype.

PMID:12913066 SUPPORT In Vitro

"associates and colocalizes with monoubiquitin and elongates ubiquitin half-life. "

Defines the biochemical function — ubiquitin stabilisation — that is lost in disease.

Impaired Ubiquitin-Dependent Protein Turnover

Reduced ubiquitin availability and deubiquitinase activity slow proteasome-mediated protein catabolism in neurons, so misfolded and damaged proteins are cleared less efficiently and ubiquitinated conjugates accumulate. In the Uchl1-mutant gad mouse this is seen directly as progressive accumulation of ubiquitin-positive deposits along sensory and motor pathways.

proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 ↓ DECREASED

Downstream

Dying-Back Axonal Degeneration Failure of ubiquitin-dependent proteostasis is most damaging to the distal ends of long axons, where proteins must be maintained far from the soma, producing a dying-back pattern of degeneration.

Show evidence (4 references)

PMID:10471497 SUPPORT Model Organism

"As Uch-l1 is thought to stimulate protein degradation by generating free monomeric ubiquitin, the gad mutation appears to affect protein turnover."

States the mechanistic inference directly: loss of Uch-l1, which generates the free monomeric ubiquitin that drives protein degradation, impairs protein turnover. Model-organism evidence.

PMID:10471497 SUPPORT Model Organism

"occur retrogradely along the sensory and motor nervous systems. "

Documents retrograde accumulation of amyloid-beta and ubiquitin-positive deposits along the affected sensory and motor systems in the Uchl1-mutant mouse.

PMID:32656641 SUPPORT Human Clinical

"is critically important in maintaining free ubiquitin levels through the addition or removal of ubiquitin to poly-ubiquitin chains, and thus has a central role in cytoplasmic protein degradation"

A report of an affected recessive UCHL1 family states the mechanistic link explicitly: UCH-L1 maintains free ubiquitin levels and thereby has a central role in cytoplasmic protein degradation.

+ 1 more reference

Dying-Back Axonal Degeneration

The cardinal cellular lesion is a distal-to-proximal ("dying-back") axonal degeneration with formation of axonal spheroids at nerve terminals, established in the Uchl1-mutant gad mouse and matching the length-dependent clinical pattern in patients. Long, thin, highly transport-dependent projections — retinal ganglion cell axons in the optic nerve, corticospinal tract axons, and the ascending dorsal-column sensory axons — are selectively vulnerable.

axonal transport GO:0098930 ⚠ ABNORMAL neuron apoptotic process GO:0051402 ↑ INCREASED

Downstream

Retinal Ganglion Cell and Optic Nerve Degeneration Retinal ganglion cell axons are among the longest, thinnest and most transport-dependent CNS projections and degenerate first in this disease.

Cerebellar Degeneration Cerebellar neurons and their projections degenerate, producing the cerebellar syndrome. The intermediate steps between impaired proteostasis and Purkinje-cell loss are not established in UCHL1 disease.

Dorsal Column and Sensory Axon Degeneration Ascending dorsal-column sensory axons and peripheral sensory axons undergo length-dependent dying-back degeneration.

Corticospinal Tract Degeneration The long descending corticospinal motor axons degenerate distally, producing upper motor neuron dysfunction.

Show evidence (2 references)

PMID:10471497 SUPPORT Model Organism

"the mutant is characterized by 'dying-back' type axonal "

Establishes dying-back axonal degeneration with terminal spheroid bodies as the pathological signature of Uchl1 loss of function. Model-organism evidence.

PMID:11555633 SUPPORT Model Organism

"display sensory ataxia followed by posterior paralysis and "

The gad mouse recapitulates the human sequence — sensory (dorsal column) involvement first, then progressive paralysis — supporting the shared dying-back mechanism. Model-organism evidence.

Retinal Ganglion Cell and Optic Nerve Degeneration

Progressive loss of retinal ganglion cells and their optic nerve axons produces bilateral optic atrophy, the usual presenting feature, with progressive visual decline to blindness during childhood.

retinal ganglion cell CL:0000740

neuron apoptotic process GO:0051402 ↑ INCREASED

retina UBERON:0000966 optic nerve UBERON:0000941

Downstream

Optic Atrophy Retinal ganglion cell axon loss is seen clinically as optic atrophy.

Progressive Visual Loss Cumulative retinal ganglion cell loss produces progressive decline of visual function.

Blindness Progressive retinal ganglion cell loss culminates in blindness during childhood.

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"progressive neurodegenerative syndrome featuring childhood onset blindness, "

Childhood-onset blindness is the defining ophthalmic outcome of optic nerve degeneration in the index family.

PMID:28007905 SUPPORT Human Clinical

"siblings developed childhood-onset optic atrophy, followed by spasticity and "

Independently documents childhood-onset optic atrophy as the first manifestation in a second family.

Cerebellar Degeneration

Degeneration of the cerebellar cortex and its output pathways produces progressive cerebellar ataxia and nystagmus. Purkinje cells, which carry the sole output of the cerebellar cortex and are exceptionally dependent on proteostasis across a very large dendritic and axonal compartment, are the presumed principal target, by analogy with the conserved cerebellar-degeneration module; UCHL1-specific histopathological confirmation in humans is not available (see `discussions`).

Purkinje cell CL:0000121

neuron apoptotic process GO:0051402 ↑ INCREASED

cerebellum UBERON:0002037

Downstream

Cerebellar Ataxia Loss of cerebellar cortical output produces progressive gait and limb ataxia.

Nystagmus Cerebellar oculomotor dysfunction, compounded by early visual loss, produces nystagmus.

Show evidence (1 reference)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Documents the cerebellar clinical syndrome (ataxia, nystagmus). Scored PARTIAL because the cited source establishes the clinical cerebellar phenotype rather than Purkinje-cell degeneration histologically.

Dorsal Column and Sensory Axon Degeneration

Length-dependent degeneration of large sensory axons and their ascending dorsal-column projections produces impaired vibration and joint-position sense — the "dorsal column dysfunction" of the original description — and, in some patients, a clinically evident peripheral neuropathy. This is the human counterpart of the gracile-tract axonal dystrophy that names the gad mouse. Conformance caveat: this node declares conformance to the `peripheral_axonal_degeneration` module, but only its axonal arm applies. The module node also carries Schwann cells with decreased myelination and axon ensheathment; UCHL1 disease is a primary axonopathy with no established demyelinating component, so those descriptors are deliberately omitted rather than overlooked.

sensory neuron CL:0000101

axonal transport GO:0098930 ⚠ ABNORMAL

spinal cord dorsal column UBERON:0005373 peripheral nerve UBERON:0001021

Downstream

Impaired Proprioception Dorsal column degeneration produces loss of joint position sense.

Impaired Vibratory Sensation Large-fibre and dorsal column degeneration produces loss of vibration sense.

Peripheral Neuropathy Distal degeneration of peripheral sensory (and motor) axons produces a clinical neuropathy.

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Dorsal column dysfunction is a defining component of the syndrome in the index family (the source spells it "dysfuction").

PMID:11555633 SUPPORT Model Organism

"gracile axonal dystrophy (gad) mutant mice, "

The Uchl1-mutant mouse is named for gracile (dorsal-column) axonal dystrophy, the animal counterpart of the human dorsal-column lesion. Model-organism evidence.

Corticospinal Tract Degeneration

Distal degeneration of the long descending corticospinal axons of upper motor neurons produces spasticity, hyperreflexia and extensor plantar responses in a lower-limb-predominant (paraparetic) distribution that eventually generalises to tetraparesis — the feature that places this disorder in the hereditary spastic paraplegia nomenclature as SPG79B.

upper motor neuron CL:0008048

neuron apoptotic process GO:0051402 ↑ INCREASED

corticospinal tract UBERON:0002707 spinal cord UBERON:0002240

Downstream

Spastic Paraplegia Corticospinal degeneration produces lower-limb-predominant spasticity and weakness.

Upper Motor Neuron Dysfunction Loss of corticospinal input produces upper motor neuron signs.

Tetraparesis Progressive, generalising corticospinal involvement ultimately produces four-limb weakness.

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"upper motor neuron dysfunction. Through homozygosity mapping of the affected "

Documents spasticity with upper motor neuron dysfunction in the index family.

PMID:29735986 SUPPORT Human Clinical

"clinical features. Recessive, disease causing variants in Ubiquitin C-terminal "

Places the disorder within the hereditary spastic paraplegia nomenclature (SPG79) as a recessive UCHL1 disorder characterised by spasticity and paraplegia.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

21

Cardiovascular 2

Hypertrophic Cardiomyopathy HP:0001639

Onset: YOUNG ADULT

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"possibility that hypertrophic cardiomyopathy may be an additional feature of the "

Scored PARTIAL because the authors themselves frame hypertrophic cardiomyopathy as a possible additional feature based on a single family, not an established one.

Sudden Cardiac Death HP:0001645

Onset: MIDDLE AGE

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac "

Documents sudden cardiac death in both affected siblings.

Eye 4

Optic Atrophy HP:0000648

Course: PROGRESSIVE Onset: CHILDHOOD

Show evidence (2 references)

PMID:28007905 SUPPORT Human Clinical

"siblings developed childhood-onset optic atrophy, followed by spasticity and "

Documents childhood-onset optic atrophy as the first manifestation in three affected siblings.

PMID:29735986 SUPPORT Human Clinical

"spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "

Lists optic atrophy among the defining features of SPG79.

Progressive Visual Loss HP:0000529

Onset: CHILDHOOD

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"progressive disease resembling Behr syndrome, starting with visual impairment, "

Documents visual impairment as the childhood-onset presenting feature of a slowly progressive UCHL1 disease course.

Blindness HP:0000618

Onset: CHILDHOOD

Show evidence (1 reference)

PMID:23359680 SUPPORT Human Clinical

"progressive neurodegenerative syndrome featuring childhood onset blindness, "

Childhood-onset blindness is the first-listed defining feature of the syndrome.

Nystagmus HP:0000639

Show evidence (1 reference)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Nystagmus is listed among the defining features of the syndrome.

Head and Neck 1

Facial Dysmorphism Abnormal facial shape HP:0001999

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"she had facial dysmorphism including low nasal bridge, micrognathia, and large, low-set ears"

Documents the specific dysmorphic features; the sibling had the same triad plus facial hypotonia.

Limbs 1

Foot Deformity Pes cavus HP:0001761

HPO binding uses Pes cavus as the closest available term. The deformity documented in the cited family is equinovarus; pes cavus is separately recorded in Table 1 for patients of two of the four published families.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"presented with distal upper and lower limb wasting and equinovarus deformity due to peripheral neuropathy and spastic paraparesis"

Documents equinovarus foot deformity attributed to the combined neuropathy and spastic paraparesis. Scored PARTIAL because the quoted deformity is equinovarus rather than the pes cavus the HPO term names.

Musculoskeletal 2

Spastic Paraplegia Spastic paraparesis HP:0002313

Course: PROGRESSIVE

Show evidence (2 references)

PMID:29735986 SUPPORT Human Clinical

"spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "

Spasticity and paraplegia are the defining motor features of SPG79.

PMID:32656641 SUPPORT Human Clinical

"progressive spasticity, weakness, and atrophy of the lower legs and ataxia. "

Documents progressive lower-limb spasticity, weakness and atrophy in two UCHL1-deletion siblings.

Scoliosis HP:0002650

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"also developed scoliosis, leading to respiratory problems. In their late 30's, "

Documents scoliosis with consequent respiratory problems in two siblings with a homozygous UCHL1 deletion.

Nervous System 4

Cerebellar Ataxia HP:0001251

Course: PROGRESSIVE

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Cerebellar ataxia is a core component of the defining clinical constellation.

PMID:29735986 SUPPORT Human Clinical

"spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "

Independently lists cerebellar signs among the defining features of SPG79.

Cognitive Impairment FREQUENT HP:0100543

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"Seizures − − + − − − + − − − Cognitive impairmentNA + + − − − + + − − Facial dysmorphismNANANANANANA + + + +"

The "Cognitive impairment" row of Table 1, which tabulates the ten patients reported across the four published SPG79B families: one not assessed (NA) and 4 of the remaining 9 scored positive. That 4/9 (44%) denominator counts cognitive impairment specifically and places it in the FREQUENT band (30-79%). Rendered from the source HTML table, so the row runs the label and first cell together.

PMID:32656641 REFUTE Human Clinical

"Cognitive function was also unaffected in P2."

Counter-evidence recorded deliberately: cognition was explicitly normal in this patient (and, stated separately, in the index sibling). Cognitive impairment is therefore not a universal feature, which is why the band is FREQUENT rather than VERY_FREQUENT.

Seizures OCCASIONAL HP:0001250

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"Lost ambulation + + + + + + + + + + Seizures − − + − − − + − − − Cognitive impairmentNA + + − − − + + − −"

The "Seizures" row of Table 1, covering all ten patients reported across the four published SPG79B families: 2 positive of 10 (20%). That denominator counts seizures specifically and places them in the OCCASIONAL band (5-29%).

PMID:32656641 SUPPORT Human Clinical

"Additional, less consistently described features include epilepsy, cognitive impairment, facial myokymia, fasciculations, and reduced peripheral sensation, reflecting the widespread expression of UCHL1 in most neuronal cells."

Independently confirms epilepsy as a real but inconsistent feature of SPG79. This is an aggregate sentence covering several features, so it supports the disease-phenotype association only; the OCCASIONAL band rests on the Table 1 seizure row above.

Peripheral Neuropathy VERY_FREQUENT HP:0009830

Show evidence (5 references)

PMID:32656641 SUPPORT Human Clinical

"Both siblings presented in childhood with motor developmental delay, optic atrophy leading to progressive visual loss, cerebellar ataxia, spastic paraparesis, and motor neuropathy."

Documents motor neuropathy as part of the childhood-onset presentation in the recessive UCHL1-deletion siblings.

PMID:32656641 SUPPORT Human Clinical

"there was length-dependent atrophy and sensory loss in-keeping with a peripheral neuropathy"

Documents the length-dependent atrophy and sensory loss on examination that define the clinical peripheral neuropathy, supporting the length-dependent dying-back mechanism curated in `pathophysiology`.

PMID:32656641 SUPPORT Human Clinical

"In addition to spasticity, ataxia, and peripheral neuropathy, SPG79 is characterized by severe optic atrophy in the first decade of life."

Peripheral neuropathy is named as a defining component of SPG79 alongside spasticity, ataxia and optic atrophy. This is an aggregate statement, so it supports the disease-phenotype association only; the frequency band rests on the Table 1 row below.

+ 2 more references

Other 7

Impaired Proprioception HP:0010831

Show evidence (1 reference)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Dorsal column dysfunction — decreased vibration and position sense — is a defining feature of the syndrome.

Impaired Vibratory Sensation HP:0002495

Show evidence (1 reference)

PMID:23359680 SUPPORT Human Clinical

"cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "

Dorsal column dysfunction, which comprises reduced vibration and position sense, is a defining feature of the syndrome.

Upper Motor Neuron Dysfunction HP:0002493

Show evidence (3 references)

PMID:23359680 SUPPORT Human Clinical

"upper motor neuron dysfunction. Through homozygosity mapping of the affected "

Upper motor neuron dysfunction is explicitly part of the defining phenotype.

PMID:32656641 SUPPORT Human Clinical

"She had marked lower limb spasticity, extensor plantar responses and ankle clonus, and a severe scoliosis."

Documents the pyramidal examination findings — spasticity, extensor plantars and clonus — in a recessive UCHL1 patient.

PMID:32656641 SUPPORT Human Clinical

"Deep tendon reflexes were absent in the upper and lower limbs"

Supports the caveat in the description: reflexes are absent or reduced rather than brisk, because of the coexisting peripheral neuropathy. The sibling likewise had reflexes "pathologically reduced in upper and lower limbs, and plantar responses were extensor".

Loss of Ambulation VERY_FREQUENT HP:0002505

Course: PROGRESSIVE

Show evidence (3 references)

PMID:32656641 SUPPORT Human Clinical

"Cerebellar signs + + + + + + + + + + Lost ambulation + + + + + + + + + + Seizures − − + − − − + − − −"

The "Lost ambulation" row of Table 1, which tabulates all ten patients reported across the four published SPG79B families, is positive ("+") for every patient. This 10/10 denominator counts loss of ambulation specifically and is the basis for the VERY_FREQUENT band.

PMID:32656641 SUPPORT Human Clinical

"She became non-ambulant following a femoral fracture aged 38 years."

Documents loss of ambulation in the index patient, and the intercurrent fracture that precipitated it.

PMID:32656641 SUPPORT Human Clinical

"He became non-ambulant aged 8 years following surgical correction of his foot deformity."

Documents loss of ambulation in the affected sibling at a much earlier age, illustrating the wide within-family variability in when walking is lost.

Ophthalmoparesis OCCASIONAL HP:0000597

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"revealed bilateral optic atrophy, both pendular and gaze induced nystagmus, ophthalmoparesis, facial dysmorphism"

Documents ophthalmoparesis on examination in a recessive UCHL1 patient.

PMID:32656641 SUPPORT Human Clinical

"Nystagmus + + + + + + + + − + OphthalmoparesisNANANA − + − − − − + Pyramidal signs + + + + + + + + + + Spasticity"

The "Ophthalmoparesis" row of Table 1: three patients not assessed (NA) and 2 of the remaining 7 positive (29%). That denominator counts ophthalmoparesis specifically and places it at the top of the OCCASIONAL band (5-29%). Rendered from the source HTML table, so the row label runs into the first cells.

Tetraparesis HP:0002273

Course: PROGRESSIVE

Progression to tetraparesis is stated in the Orphanet/MONDO clinical definition of this entity (Orphanet:352654 / MONDO:0014209). No abstract-level quotable primary-literature statement of tetraparesis was found, so this phenotype is recorded without an evidence item rather than with a fabricated snippet, per the project SOP on unverifiable claims.

Nocturnal Hypoventilation HP:0002877

Onset: YOUNG ADULT

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"From the age of 39, she developed nocturnal hypoventilation and was commenced on overnight non-invasive ventilation."

Documents nocturnal hypoventilation and the initiation of overnight non-invasive ventilation in a recessive UCHL1 patient.

🧬

Genetic Associations

1

UCHL1

Gene: UCHL1 hgnc:12513 relationship_type: CAUSATIVE

Show evidence (4 references)

PMID:23359680 SUPPORT Human Clinical

"binding domain of UCHL1 (UCHL1(GLU7ALA)), shared by all affected subjects. As "

Establishes the homozygous UCHL1 p.Glu7Ala variant, shared by all affected members of the index family, as the cause of the syndrome.

PMID:28007905 SUPPORT Human Clinical

"UCHL1, c.533G > A (p.Arg178Gln) and c.647C > A (p.Ala216Asp), cosegregating with "

Independent confirmation in a second family with compound heterozygous UCHL1 variants cosegregating with the phenotype.

PMID:29735986 SUPPORT Human Clinical

"hydrolase-L1 (UCHL1) gene have been implicated as a cause for SPG79 in two "

A third independent family, establishing UCHL1 as the SPG79 gene.

+ 1 more reference

🔬

Variants

5

UCHL1 p.Glu7Ala Pathogenic

Gene: UCHL1 hgnc:12513

The index homozygous missense allele (consanguineous family). Glu7 lies within the ubiquitin-binding region; the substitution reduces ubiquitin affinity at least sevenfold, near-completely abolishes hydrolase activity, and is predicted to obstruct correct positioning of the substrate for tunnelling beneath the cross-over loop spanning the catalytic cleft, giving a >100-fold loss of catalytic efficiency.

Show evidence (1 reference)

PMID:23359680 SUPPORT In Vitro

"resulted in a >100-fold reduction in the efficiency of UCHL1(GLU7ALA) relative "

Quantifies the catalytic consequence of the index disease allele.

UCHL1 p.Ala216Asp Pathogenic

Gene: UCHL1 hgnc:12513

A compound-heterozygous missense allele that renders the recombinant protein insoluble — a straightforward loss-of-function mechanism.

Show evidence (1 reference)

PMID:28007905 SUPPORT In Vitro

"consequences as the insoluble Ala216Asp variant leads to loss of function, "

Documents insolubility and consequent loss of function for this allele.

UCHL1 p.Arg178Gln Pathogenic

Gene: UCHL1 hgnc:12513

A compound-heterozygous missense allele with a counter-intuitive functional consequence: purified recombinant p.Arg178Gln protein shows roughly four-fold increased hydrolytic activity, because Arg178 normally holds the catalytic histidine in a partially inactive arrangement. Later biophysical work attributed the gain to a kcat effect and a more reactive catalytic cysteine, with widespread changes in protein dynamics rather than a rearranged active site.

Show evidence (2 references)

PMID:28007905 SUPPORT In Vitro

"ubiquitin hydrolase assays showed a 4-fold increased hydrolytic activity of the "

Documents the increased catalytic activity of this disease allele.

PMID:38185323 SUPPORT In Vitro

"Enzyme kinetics show the activation is due to a kcat effect despite a slightly "

Provides the structural/kinetic basis of the activating effect of p.Arg178Gln.

UCHL1 c.459+2T>C Pathogenic

Gene: UCHL1 hgnc:12513

A novel homozygous canonical splice-donor variant identified by whole-exome sequencing in an Indian family with two affected siblings and validated by Sanger sequencing.

Show evidence (1 reference)

PMID:29735986 SUPPORT Human Clinical

"gene (NM_004181.4: c.459+2T>C). The variant was identified by "

Reports the homozygous splice-site allele in a third SPG79 family.

UCHL1 p.Gly210del Pathogenic

Gene: UCHL1 hgnc:12513

A novel homozygous in-frame single-codon deletion (c.627_629del) identified in two siblings with a Behr-syndrome-like presentation who additionally developed hypertrophic cardiomyopathy.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1."

Reports the in-frame deletion allele in a fourth family.

💊

Medical Actions

9

Supportive and Multidisciplinary Care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

No disease-modifying therapy exists. Management is supportive and multidisciplinary: low-vision rehabilitation, physiotherapy and spasticity management, mobility aids, orthopaedic assessment of scoliosis, respiratory monitoring, cardiac surveillance and genetic counselling.

Low-Vision Rehabilitation

Action: Rehabilitation NCIT:C15315

Visual aids, educational support and low-vision rehabilitation for the early, severe and ultimately profound visual impairment.

Physical Therapy for Spasticity and Ataxia

Action: Physical Therapy NCIT:C15302

Physiotherapy, stretching, orthoses and gait training to manage progressive spasticity, ataxia and contracture risk.

Antispasticity Pharmacotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: baclofen CHEBI:2972 tizanidine CHEBI:63629 botulinum toxin (no CHEBI/NCIT chemical-entity term available)

Symptomatic spasticity management is extrapolated from general hereditary spastic paraplegia practice rather than from any UCHL1-specific study: oral baclofen or tizanidine, focal botulinum toxin, and intrathecal baclofen in severe generalised spasticity. No UCHL1-specific response rate or adverse-event estimate exists, and symptomatic measures in hereditary spastic paraplegia as a class remain unsatisfactory.

Show evidence (1 reference)

PMID:35163618 SUPPORT Other

"Though modern medical interventions help recognize and manage the "

Scored PARTIAL and explicitly class-extrapolated: this hereditary spastic paraplegia review supports symptomatic management for the HSP class as a whole (and notes that symptomatic measures remain below satisfaction), not UCHL1/SPG79B-specific efficacy.

Cardiac Surveillance and Management

Action: therapeutic procedure Ontology label: Therapeutic Procedure NCIT:C49236

Given the report of hypertrophic cardiomyopathy causing sudden cardiac death in both affected siblings of one family, cardiac follow-up and treatment are recommended in UCHL1-related neurodegeneration.

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"highlights the importance of cardiac follow-up and treatment in "

Directly supports cardiac follow-up and treatment as part of management.

PMID:32656641 SUPPORT Human Clinical

"Given the symptomatic features of a possible mitochondrial disorder, in particular optic atrophy, a cardiac evaluation was carried out in both patients."

Documents echocardiographic cardiac evaluation as the surveillance modality that detected the cardiomyopathy in this family.

Heart Failure Pharmacotherapy for UCHL1-Associated Cardiomyopathy

Action: Pharmacotherapy NCIT:C15986

Agent: ACE inhibitor NCIT:C247 beta-blocker NCIT:C29576

Both affected siblings of the UCHL1-deletion family were treated with ACE inhibitors and beta-blockers, and their cardiac function stabilised. This is standard cardiomyopathy therapy rather than a disease-specific intervention, and it did not prevent eventual sudden cardiac death in either patient — an important limitation to convey when counselling.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"Both siblings were commenced on ACE inhibitors and beta-blockers and their cardiac function stabilized."

Documents the agents used and the short-term stabilisation of cardiac function. Scored PARTIAL because this is an uncontrolled two-patient observation, and the same source records that both siblings nonetheless died of sudden cardiac death.

Non-Invasive Ventilation

Action: non-invasive ventilation Ontology label: Therapeutic Procedure NCIT:C49236

Overnight non-invasive ventilation for the nocturnal hypoventilation that follows scoliosis-related restrictive respiratory compromise in advanced disease. NCIT has no clinical-action term for non-invasive ventilation reachable from Clinical Intervention or Procedure, so the generic therapeutic-procedure term is used and the specificity is carried in the name and description.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"she developed nocturnal hypoventilation and was commenced on overnight non-invasive ventilation."

Documents initiation of overnight non-invasive ventilation in a recessive UCHL1 patient.

Scoliosis Surgery

Action: orthopedic surgical procedure Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Severe progressive scoliosis may require spinal surgery; it was performed at age 16 in the index patient of the UCHL1-deletion family, whose scoliosis later contributed to restrictive respiratory compromise.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"she developed progressive lower limb spasticity, foot deformities, and severe scoliosis requiring spinal surgery aged 16 years"

Documents spinal surgery for severe scoliosis in a recessive UCHL1 patient.

Genetic Counseling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Autosomal recessive inheritance carries a 25% recurrence risk for siblings; carrier testing and reproductive counselling should be offered. Counselling should also address the distinct autosomal dominant disorder caused by heterozygous UCHL1 loss-of-function (SPG79A), which may be relevant to the wider family.

🔬

Diagnosis

5

Molecular Genetic Testing

Diagnosis rests on identifying biallelic pathogenic UCHL1 variants. Because the clinical picture (optic atrophy plus spastic ataxia) is shared by many genetically distinct disorders, exome/genome sequencing or a broad hereditary-spastic-paraplegia, hereditary-ataxia or inherited-optic-neuropathy gene panel — rather than single-gene testing — is the appropriate first-line approach.

Show evidence (2 references)

PMID:23359680 SUPPORT Human Clinical

"individuals followed by whole-exome sequencing of the index case, we identified "

The disease gene was, and continues to be, identified by exome sequencing.

PMID:32656641 SUPPORT Human Clinical

"diagnosis is based on gene panel testing or whole-exome/genome sequencing."

States that molecular diagnosis in this clinically defined group rests on panel or exome/genome sequencing.

Ophthalmological assessment

Fundoscopy, visual acuity and visual-field testing, optical coherence tomography and visual evoked potentials document the optic neuropathy. Because optic atrophy can be asymptomatic and under-recognised, the optic nerves should be assessed deliberately in anyone presenting with ataxia and spasticity.

Results: Bilateral optic disc pallor with reduced acuity.

Show evidence (1 reference)

PMID:42375238 SUPPORT Human Clinical

"Clinicians should carefully assess the optic nerves in individuals "

Explicit clinical recommendation to examine the optic nerves in patients presenting with ataxia and spasticity, since optic atrophy can be asymptomatic and under-reported yet is decisive for directing genomic testing in UCHL1 disease. (Reported for the allelic dominant disorder; the assessment recommendation applies across UCHL1-related disease.)

Metabolic and CSF workup (exclusion)

There is no diagnostic biochemical test for this disease; metabolic and CSF studies serve to exclude the treatable and mitochondrial mimics that the optic-atrophy-plus presentation raises. In the recessive UCHL1 family a detailed panel — acylcarnitines, urinary organic acids, very long chain fatty acids, pristanic and phytanic acids, lysosomal enzymes, copper, caeruloplasmin and acanthocytes — was entirely normal, as were CSF constituents. A normal workup of this kind therefore supports, rather than argues against, a UCHL1 diagnosis.

Results: Normal metabolic panel and normal CSF constituents.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"Detailed laboratory work-up (including acylcarnitines, urinary organic acids, very long chain fatty acids, pristanic and phytanic acids, lysosomal enzymes, copper, caeruloplasmin, and acanthocytes) was normal. CSF constituents were normal in both cases."

Documents the exclusion panel and its normal result in molecularly confirmed recessive UCHL1 disease.

Nerve conduction studies and electrophysiology

Nerve conduction studies and EMG are used to characterise the peripheral neuropathy. A practical caveat is recorded in the literature: in advanced disease the foot deformity and swelling may make neurophysiological testing technically impossible, so a negative or absent study should not be read as excluding neuropathy.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"Unfortunately, neurophysiological testing was not technically possible due to the degree of foot deformity and swelling."

Scored PARTIAL: this documents a limitation of electrophysiology in advanced disease rather than a positive diagnostic yield. It is curated because the practical caveat matters when interpreting a missing study.

Cardiac surveillance

Echocardiographic and rhythm surveillance is recommended in UCHL1-related neurodegeneration because hypertrophic cardiomyopathy with sudden cardiac death has been reported.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"highlights the importance of cardiac follow-up and treatment in "

Directly recommends cardiac follow-up in UCHL1-associated neurodegeneration.

📈

Progression

3

Early

Age: Onset 2-10 years across the ten published patients

Childhood-onset visual loss from optic atrophy is the first symptom in almost every reported patient, accompanied by gait imbalance and subtle pyramidal or neuropathic signs. Two patients instead presented with developmental delay and one with seizures.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"In all cases described to date, the first symptom was of childhood-onset visual loss due to optic atrophy."

Establishes childhood visual loss as the near-invariant first stage of the disease course.

Intermediate

A definite spastic-ataxic gait emerges with established optic atrophy, distal wasting and foot deformity from the motor neuropathy, and falls. The tempo is slow and the course chronic and progressive rather than episodic or relapsing.

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"The subsequent disease course was characterized by varying degrees of spasticity and cerebellar ataxia."

Establishes the spastic-ataxic stage that follows the visual presentation.

PMID:32656641 SUPPORT Human Clinical

"Both patients had a childhood-onset, slowly progressive disease "

Characterises the tempo as childhood-onset and slowly progressive.

Advanced

Age: Reported ages at last examination 7-65 years, so the course can extend over decades

Severe visual disability or blindness, loss of independent ambulation (recorded in all ten published patients), progressive four-limb involvement and contractures. In one family scoliosis produced restrictive respiratory compromise, and both siblings died suddenly of hypertrophic cardiomyopathy at 40 and 43 years. No validated progression scale, median disease duration or intervention window exists.

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"also developed scoliosis, leading to respiratory problems. In their late 30's, "

Documents the late-stage complications — scoliosis with respiratory compromise, then adult-onset hypertrophic cardiomyopathy — in the longest-followed family.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Ultra-rare, and reported only as individual kindreds. As of 2020 only four families (ten patients) had been described worldwide. A qualitative band is used rather than a numeric Orphanet class because no source gives a numeric rate — Orphanet (ORPHA:352654) lists the entity without a documented prevalence figure.

Show evidence (2 references)

PMID:32656641 SUPPORT Human Clinical

"To date, mutations in UCHL1 have been described in only three families"

At the time of this fourth report only three families had previously been published worldwide, supporting the ultra-rare, cases-in-literature band.

PMID:29735986 SUPPORT Human Clinical

"hydrolase-L1 (UCHL1) gene have been implicated as a cause for SPG79 in two "

At the time of this third report only two families had been published worldwide, an independent snapshot of the same ultra-rare occurrence.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia:

Behr syndrome MONDO:0008858

Overlapping Features Behr syndrome is the closest clinical mimic and the most important named-entity-confusion hazard for this disorder: it is defined by essentially the same constellation of early-onset optic atrophy, ataxia, pyramidal signs, posterior-column sensory loss and peripheral neuropathy. It is, however, a clinically defined, genetically heterogeneous mitochondrial entity, with biallelic OPA1 as its core molecularly resolved cause and OPA3, C12orf65/MTRFR and C19orf12 as additional causes, all converging on impaired mitochondrial bioenergetics. UCHL1 disease reaches the same clinical picture by an entirely different route — failure of the neuronal ubiquitin-proteasome system. Indeed one UCHL1 family was published under the Behr syndrome label as a novel genetic form of Behr syndrome, so the two entities are curated separately in dismech (`Behr_Syndrome`) and the boundary is molecular, not clinical.

Distinguishing Features

Mitochondrial bioenergetic mechanism (OPA1, OPA3, C12orf65/MTRFR, C19orf12) rather than ubiquitin-proteasome failure
Elevated blood or CSF lactate and a lactate peak on MR spectroscopy
Leigh-like basal-ganglia signal abnormality on MRI
Cytochrome-c-oxidase-deficient fibres on muscle biopsy
Multiple mitochondrial DNA deletions in skeletal muscle
Molecular testing is the definitive discriminator

Show evidence (1 reference)

PMID:32656641 SUPPORT Human Clinical

"Behr syndrome is a clinically distinct, but genetically "

States that Behr syndrome is clinically distinct but genetically heterogeneous — the reason a UCHL1 family could be reported under that label, and the reason the boundary between the two dismech entries must be drawn molecularly.

SPG79A - autosomal dominant UCHL1-related spastic ataxia Not Yet Curated MONDO:0859363

Overlapping Features The allelic autosomal dominant disorder caused by heterozygous UCHL1 loss of function, established by gene-burden analysis across 3169 ataxia and spastic-paraplegia patients and 33,141 controls, with 34 cases from 18 families. It presents later (adult or late-onset), is milder, and shows spasticity, ataxia, neuropathy and optic atrophy in varying combinations; the mechanism is UCHL1 haploinsufficiency (approximately 50% protein reduction in patient fibroblasts) rather than the near-complete loss seen in the recessive disease. It is a distinct OMIM and MONDO entity and is not curated here.

Distinguishing Features

Monoallelic (heterozygous) UCHL1 loss-of-function variant
Autosomal dominant family history across generations
Adult or late-onset course rather than childhood onset
Milder and more variable phenotype, with optic atrophy sometimes asymptomatic
Approximately 50% UCHL1 protein reduction rather than near-complete loss of function

Show evidence (2 references)

PMID:35986737 SUPPORT Human Clinical

"and functional studies established haploinsufficiency of UCHL1 as a novel "

Establishes heterozygous UCHL1 haploinsufficiency as a separate, dominant disease mechanism.

PMID:39030458 SUPPORT Human Clinical

"a severe, complex autosomal recessive spastic paraplegia (HSP79) [1] [2] "

Explicitly contrasts the severe complex autosomal recessive UCHL1 disorder (this entry) with the more recently described dominant UCHL1 disease.

Hereditary spastic paraplegia - other genetic forms MONDO:0019064

Overlapping Features Because spastic paraplegia is a defining feature, the broader hereditary spastic paraplegia group — in particular the complex/complicated forms that combine pyramidal signs with optic atrophy, ataxia or neuropathy, such as SPG7 (paraplegin), AFG3L2, SPG11 (spatacsin) and MFN2 — must be considered. Most of those combine spasticity or neuropathy with optic atrophy through mitochondrial mechanisms, whereas UCHL1 disease is a neuronal ubiquitin/proteostasis disorder. Other frequently listed phenocopies include OPA1, WFS1, SACS, KIF1A, CAPN1, FDXR, PNPT1, Friedreich ataxia, and the treatable metabolic spastic paraplegias. dismech curates the group entry `Hereditary_Spastic_Paraplegia`; this disorder is SPG79B within that nomenclature but is curated as a separate entity because its ubiquitin-proteasome mechanism and its optic-atrophy-first natural history are distinctive.

Distinguishing Features

Optic atrophy preceding the motor syndrome
Prominent dorsal-column sensory loss with impaired vibration and position sense
Biallelic UCHL1 variants on sequencing

Show evidence (1 reference)

PMID:29735986 SUPPORT Human Clinical

"Spastic Paraplegia-79 (SPG79) is an autosomal recessive type of childhood onset "

Places this disorder within the hereditary spastic paraplegia nomenclature as SPG79.

🐁

Animal Models

1

Uchl1(gad) - spontaneous in-frame deletion of Uchl1 exons 7-8 Mus musculus

The gracile axonal dystrophy (gad) mouse is the reference animal model. It is an autosomal recessive spontaneous mutant carrying an in-frame deletion of Uchl1 exons 7 and 8 that removes a 42-amino-acid segment containing a catalytic residue. gad mice show early sensory ataxia followed by motor ataxia and posterior paralysis, with dying-back axonal degeneration, terminal spheroid bodies, and retrograde accumulation of ubiquitin-positive deposits along sensory and motor pathways — closely paralleling the human dorsal-column-plus-corticospinal phenotype.

Species

Mus musculus

Genotype

Uchl1(gad) - spontaneous in-frame deletion of Uchl1 exons 7-8

Genes

UCHL1 hgnc:12513

Show evidence (3 references)

PMID:10471497 SUPPORT Model Organism

"Here we find that the gad mutation is caused by an in-frame deletion "

Establishes the Uchl1 lesion underlying the gad mouse.

PMID:10471497 SUPPORT Model Organism

"shows sensory ataxia at an early stage, followed by motor ataxia at a later "

The temporal sequence in the model — sensory (dorsal column) involvement preceding motor involvement — mirrors the human disease course.

PMID:11555633 SUPPORT Model Organism

"display sensory ataxia followed by posterior paralysis and "

Independently characterises the gad phenotype and shows that concurrent Uch-L3 loss worsens it, indicating partial functional redundancy among UCH isozymes.

{ }

Source YAML

click to show

name: UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia
creation_date: "2026-08-01T00:00:00Z"
category: Mendelian
synonyms:
- early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome
- SPG79B
- spastic paraplegia 79, autosomal recessive
- childhood-onset neurodegeneration with optic atrophy
- NDGOA
description: >
  An autosomal recessive, early-onset progressive neurodegenerative disease caused by
  biallelic loss-of-function variants in UCHL1, which encodes ubiquitin C-terminal
  hydrolase L1 (UCH-L1 / PGP 9.5) — a neuron-specific deubiquitinating enzyme and one of
  the most abundant proteins in the brain. Early development is normal; affected children
  then develop optic atrophy with progressive visual loss beginning in the first decade
  and proceeding to blindness, followed by a progressive neurological decline comprising cerebellar
  ataxia, nystagmus, dorsal column dysfunction (loss of vibration and position sense) and
  spastic paraplegia with upper motor neuron signs, ultimately progressing to
  tetraparesis. The entity is designated SPG79B (OMIM 615491) in the hereditary spastic
  paraplegia nomenclature and was originally reported as childhood-onset neurodegeneration
  with optic atrophy (NDGOA). Mechanistically it is a disorder of the neuronal
  ubiquitin-proteasome system: loss of UCH-L1 hydrolase/ubiquitin-binding function
  compromises ubiquitin recycling and the free monoubiquitin pool, impairing
  ubiquitin-dependent protein turnover and producing a dying-back axonal degeneration that
  preferentially affects the long, highly transport-dependent projections of the optic
  nerve, corticospinal tracts, dorsal columns and cerebellar circuitry. It is therefore
  mechanistically distinct from — although clinically overlapping with — the mitochondrial
  optic-atrophy-plus disorders such as Behr syndrome (see `differential_diagnoses` and
  `notes`).
disease_term:
  preferred_term: early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome
  term:
    id: MONDO:0014209
    label: early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome
parents:
- Hereditary Spastic Paraplegia

progression:
- phase: Early
  age_range: Onset 2-10 years across the ten published patients
  notes: >
    Childhood-onset visual loss from optic atrophy is the first symptom in almost every
    reported patient, accompanied by gait imbalance and subtle pyramidal or neuropathic
    signs. Two patients instead presented with developmental delay and one with seizures.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all cases described to date, the first symptom was of childhood-onset visual loss due to optic atrophy."
    explanation: Establishes childhood visual loss as the near-invariant first stage of the disease course.
- phase: Intermediate
  notes: >
    A definite spastic-ataxic gait emerges with established optic atrophy, distal wasting
    and foot deformity from the motor neuropathy, and falls. The tempo is slow and the
    course chronic and progressive rather than episodic or relapsing.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The subsequent disease course was characterized by varying degrees of spasticity and cerebellar ataxia."
    explanation: Establishes the spastic-ataxic stage that follows the visual presentation.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients had a childhood-onset, slowly progressive disease "
    explanation: Characterises the tempo as childhood-onset and slowly progressive.
- phase: Advanced
  age_range: Reported ages at last examination 7-65 years, so the course can extend over decades
  notes: >
    Severe visual disability or blindness, loss of independent ambulation (recorded in
    all ten published patients), progressive four-limb involvement and contractures. In
    one family scoliosis produced restrictive respiratory compromise, and both siblings
    died suddenly of hypertrophic cardiomyopathy at 40 and 43 years. No validated
    progression scale, median disease duration or intervention window exists.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "also developed scoliosis, leading to respiratory problems. In their late 30's, "
    explanation: >
      Documents the late-stage complications — scoliosis with respiratory compromise,
      then adult-onset hypertrophic cardiomyopathy — in the longest-followed family.

inheritance:
- name: Autosomal recessive
  description: >
    The disease is inherited in an autosomal recessive manner. Reported families carry
    homozygous variants (consanguineous unions) or compound heterozygous variants in
    UCHL1, cosegregating with the phenotype. Heterozygous UCHL1 loss-of-function is a
    distinct, later-onset autosomal dominant disorder (SPG79A) rather than a carrier
    state for this entity — see `notes`.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a previously undescribed homozygous missense mutation within the ubiquitin "
    explanation: >
      The index family comprised three affected siblings from a consanguineous union
      sharing a homozygous UCHL1 missense variant — the classic recessive architecture.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic Paraplegia-79 (SPG79) is an autosomal recessive type of childhood onset "
    explanation: Independently states the autosomal recessive, childhood-onset nature of SPG79.

pathophysiology:
- name: Biallelic UCHL1 Loss of Function
  biological_scale: MOLECULAR
  description: >
    UCHL1 encodes ubiquitin C-terminal hydrolase L1, a neuron-specific
    (and testis/ovary-expressed) cysteine-protease deubiquitinating enzyme that is among
    the most abundant proteins in the brain. Reported disease alleles compromise the
    enzyme in several distinct ways: the index p.Glu7Ala allele lies in the
    ubiquitin-binding region and causes a >7-fold loss of ubiquitin affinity with near
    complete loss of hydrolase activity (>100-fold reduction in catalytic efficiency);
    p.Ala216Asp renders the protein insoluble (loss of function); a canonical splice-site
    variant (c.459+2T>C) and an in-frame deletion (p.Gly210del) have also been reported.
    Notably one allele, p.Arg178Gln, paradoxically increases hydrolytic turnover, so the
    unifying lesion is loss of normal UCH-L1 function/steady-state protein rather than
    strictly reduced catalysis (see `mechanistic_hypotheses`).
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  molecular_functions:
  - preferred_term: cysteine-type deubiquitinase activity
    term:
      id: GO:0004843
      label: cysteine-type deubiquitinase activity
    modifier: DECREASED
  - preferred_term: ubiquitin binding
    term:
      id: GO:0043130
      label: ubiquitin binding
    modifier: DECREASED
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In vitro, the mutation led to a near complete loss of UCHL1 hydrolase activity. "
    explanation: Directly demonstrates that the disease allele abolishes UCH-L1 hydrolase activity.
  - reference: PMID:27515257
    reference_title: "Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UCH-L1 is not essential for neuronal development but it is absolutely required for the maintenance of axonal integrity"
    explanation: >
      Explains the natural history: UCH-L1 is dispensable for neuronal development —
      hence the normal early development of affected children — but is absolutely
      required for maintenance of axonal integrity thereafter, which is why the disease
      is degenerative rather than malformative.
  - reference: PMID:27515257
    reference_title: "Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "it is estimated to make up 1-5% of total neuronal protein"
    explanation: >
      Quantifies the extraordinary neuronal abundance of UCH-L1, which underlies why its
      loss is tolerated poorly and specifically by neurons.
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "compared with WT, exhibited at least sevenfold reduced affinity for ubiquitin. "
    explanation: Isothermal titration calorimetry quantifies the loss of ubiquitin binding by the p.Glu7Ala protein.
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UCHL1 protein levels in fibroblasts measured "
    explanation: >
      Targeted mass spectrometry in patient fibroblasts showed roughly four-fold lower
      total UCHL1 than controls, establishing reduced steady-state UCH-L1 protein as the
      shared consequence in a second family.
  downstream:
  - target: Failure of Neuronal Ubiquitin Recycling
    description: >
      Loss of UCH-L1 hydrolase and ubiquitin-binding function directly impairs the
      processing and recycling of ubiquitin in neurons.
    causal_link_type: DIRECT

- name: Failure of Neuronal Ubiquitin Recycling
  biological_scale: MOLECULAR
  description: >
    UCH-L1 binds monoubiquitin with high avidity, prolongs its half-life and generates
    free monomeric ubiquitin from adducts and precursors. Loss of UCH-L1 function
    therefore depletes the neuronal free-monoubiquitin pool on which all downstream
    ubiquitin conjugation depends. This was shown in vivo in the gad mouse, in which
    UCH-L1 function is lost and neuronal monoubiquitin is reduced.
  biological_processes:
  - preferred_term: ubiquitin recycling
    term:
      id: GO:0010992
      label: ubiquitin recycling
    modifier: DECREASED
  - preferred_term: protein deubiquitination
    term:
      id: GO:0016579
      label: protein deubiquitination
    modifier: DECREASED
  evidence:
  - reference: PMID:12913066
    reference_title: Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The gad mouse, in which the function of UCH L1 is lost, exhibited a reduced "
    explanation: >
      Establishes in vivo that loss of UCH-L1 function reduces the neuronal monoubiquitin
      level. Model-organism evidence for the molecular step, not for the human phenotype.
  - reference: PMID:12913066
    reference_title: Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "associates and colocalizes with monoubiquitin and elongates ubiquitin half-life. "
    explanation: Defines the biochemical function — ubiquitin stabilisation — that is lost in disease.
  downstream:
  - target: Impaired Ubiquitin-Dependent Protein Turnover
    description: >
      A depleted free-ubiquitin pool limits substrate ubiquitination and hence flux
      through the ubiquitin-proteasome degradation system.
    causal_link_type: DIRECT

- name: Impaired Ubiquitin-Dependent Protein Turnover
  biological_scale: CELLULAR
  description: >
    Reduced ubiquitin availability and deubiquitinase activity slow proteasome-mediated
    protein catabolism in neurons, so misfolded and damaged proteins are cleared less
    efficiently and ubiquitinated conjugates accumulate. In the Uchl1-mutant gad mouse
    this is seen directly as progressive accumulation of ubiquitin-positive deposits
    along sensory and motor pathways.
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "As Uch-l1 is thought to stimulate protein degradation by generating free monomeric ubiquitin, the gad mutation appears to affect protein turnover."
    explanation: >
      States the mechanistic inference directly: loss of Uch-l1, which generates the free
      monomeric ubiquitin that drives protein degradation, impairs protein turnover.
      Model-organism evidence.
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "occur retrogradely along the sensory and motor nervous systems. "
    explanation: >
      Documents retrograde accumulation of amyloid-beta and ubiquitin-positive deposits
      along the affected sensory and motor systems in the Uchl1-mutant mouse.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is critically important in maintaining free ubiquitin levels through the addition or removal of ubiquitin to poly-ubiquitin chains, and thus has a central role in cytoplasmic protein degradation"
    explanation: >
      A report of an affected recessive UCHL1 family states the mechanistic link
      explicitly: UCH-L1 maintains free ubiquitin levels and thereby has a central role
      in cytoplasmic protein degradation.
  - reference: PMID:33159930
    reference_title: Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "contributes to the function of the ubiquitin proteasome pathway (UPP), "
    explanation: >
      A catalytically dead (C90A) knock-in mouse establishes that UCH-L1 hydrolase
      activity contributes to ubiquitin-proteasome pathway function and restrains
      autophagy activation. Model-organism evidence.
  downstream:
  - target: Dying-Back Axonal Degeneration
    description: >
      Failure of ubiquitin-dependent proteostasis is most damaging to the distal ends of
      long axons, where proteins must be maintained far from the soma, producing a
      dying-back pattern of degeneration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Dying-Back Axonal Degeneration
  biological_scale: CELLULAR
  description: >
    The cardinal cellular lesion is a distal-to-proximal ("dying-back") axonal
    degeneration with formation of axonal spheroids at nerve terminals, established in the
    Uchl1-mutant gad mouse and matching the length-dependent clinical pattern in patients.
    Long, thin, highly transport-dependent projections — retinal ganglion cell axons in
    the optic nerve, corticospinal tract axons, and the ascending dorsal-column sensory
    axons — are selectively vulnerable.
  biological_processes:
  - preferred_term: axonal transport
    term:
      id: GO:0098930
      label: axonal transport
    modifier: ABNORMAL
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the mutant is characterized by 'dying-back' type axonal "
    explanation: >
      Establishes dying-back axonal degeneration with terminal spheroid bodies as the
      pathological signature of Uchl1 loss of function. Model-organism evidence.
  - reference: PMID:11555633
    reference_title: Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "display sensory ataxia followed by posterior paralysis and "
    explanation: >
      The gad mouse recapitulates the human sequence — sensory (dorsal column) involvement
      first, then progressive paralysis — supporting the shared dying-back mechanism.
      Model-organism evidence.
  downstream:
  - target: Retinal Ganglion Cell and Optic Nerve Degeneration
    description: >
      Retinal ganglion cell axons are among the longest, thinnest and most
      transport-dependent CNS projections and degenerate first in this disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Cerebellar Degeneration
    description: >
      Cerebellar neurons and their projections degenerate, producing the cerebellar
      syndrome. The intermediate steps between impaired proteostasis and Purkinje-cell
      loss are not established in UCHL1 disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dorsal Column and Sensory Axon Degeneration
    description: >
      Ascending dorsal-column sensory axons and peripheral sensory axons undergo
      length-dependent dying-back degeneration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Corticospinal Tract Degeneration
    description: >
      The long descending corticospinal motor axons degenerate distally, producing
      upper motor neuron dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Retinal Ganglion Cell and Optic Nerve Degeneration
  biological_scale: TISSUE
  description: >
    Progressive loss of retinal ganglion cells and their optic nerve axons produces
    bilateral optic atrophy, the usual presenting feature, with progressive visual decline
    to blindness during childhood.
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  - preferred_term: optic nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  cell_types:
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive neurodegenerative syndrome featuring childhood onset blindness, "
    explanation: Childhood-onset blindness is the defining ophthalmic outcome of optic nerve degeneration in the index family.
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "siblings developed childhood-onset optic atrophy, followed by spasticity and "
    explanation: Independently documents childhood-onset optic atrophy as the first manifestation in a second family.
  downstream:
  - target: Optic Atrophy
    description: Retinal ganglion cell axon loss is seen clinically as optic atrophy.
    causal_link_type: DIRECT
  - target: Progressive Visual Loss
    description: Cumulative retinal ganglion cell loss produces progressive decline of visual function.
    causal_link_type: DIRECT
  - target: Blindness
    description: Progressive retinal ganglion cell loss culminates in blindness during childhood.
    causal_link_type: DIRECT

- name: Cerebellar Degeneration
  biological_scale: TISSUE
  conforms_to: "cerebellar_purkinje_degeneration#Purkinje Neuron Degeneration"
  description: >
    Degeneration of the cerebellar cortex and its output pathways produces progressive
    cerebellar ataxia and nystagmus. Purkinje cells, which carry the sole output of the
    cerebellar cortex and are exceptionally dependent on proteostasis across a very large
    dendritic and axonal compartment, are the presumed principal target, by analogy with
    the conserved cerebellar-degeneration module; UCHL1-specific histopathological
    confirmation in humans is not available (see `discussions`).
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: >
      Documents the cerebellar clinical syndrome (ataxia, nystagmus). Scored PARTIAL
      because the cited source establishes the clinical cerebellar phenotype rather than
      Purkinje-cell degeneration histologically.
  downstream:
  - target: Cerebellar Ataxia
    description: Loss of cerebellar cortical output produces progressive gait and limb ataxia.
    causal_link_type: DIRECT
  - target: Nystagmus
    description: >
      Cerebellar oculomotor dysfunction, compounded by early visual loss, produces
      nystagmus.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES

- name: Dorsal Column and Sensory Axon Degeneration
  biological_scale: TISSUE
  conforms_to: "peripheral_axonal_degeneration#Distal Axonal Degeneration and Demyelination"
  description: >
    Length-dependent degeneration of large sensory axons and their ascending dorsal-column
    projections produces impaired vibration and joint-position sense — the "dorsal column
    dysfunction" of the original description — and, in some patients, a clinically evident
    peripheral neuropathy. This is the human counterpart of the gracile-tract axonal
    dystrophy that names the gad mouse. Conformance caveat: this node declares
    conformance to the `peripheral_axonal_degeneration` module, but only its axonal arm
    applies. The module node also carries Schwann cells with decreased myelination and
    axon ensheathment; UCHL1 disease is a primary axonopathy with no established
    demyelinating component, so those descriptors are deliberately omitted rather than
    overlooked.
  locations:
  - preferred_term: spinal cord dorsal column
    term:
      id: UBERON:0005373
      label: spinal cord dorsal column
  - preferred_term: peripheral nerve
    term:
      id: UBERON:0001021
      label: nerve
  cell_types:
  - preferred_term: sensory neuron
    term:
      id: CL:0000101
      label: sensory neuron
  biological_processes:
  - preferred_term: axonal transport
    term:
      id: GO:0098930
      label: axonal transport
    modifier: ABNORMAL
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: >
      Dorsal column dysfunction is a defining component of the syndrome in the index
      family (the source spells it "dysfuction").
  - reference: PMID:11555633
    reference_title: Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "gracile axonal dystrophy (gad) mutant mice, "
    explanation: >
      The Uchl1-mutant mouse is named for gracile (dorsal-column) axonal dystrophy, the
      animal counterpart of the human dorsal-column lesion. Model-organism evidence.
  downstream:
  - target: Impaired Proprioception
    description: Dorsal column degeneration produces loss of joint position sense.
    causal_link_type: DIRECT
  - target: Impaired Vibratory Sensation
    description: Large-fibre and dorsal column degeneration produces loss of vibration sense.
    causal_link_type: DIRECT
  - target: Peripheral Neuropathy
    description: Distal degeneration of peripheral sensory (and motor) axons produces a clinical neuropathy.
    causal_link_type: DIRECT

- name: Corticospinal Tract Degeneration
  conforms_to: "corticospinal_tract_axonopathy#Distal Length-Dependent Degeneration of Long CNS Axons"
  biological_scale: TISSUE
  description: >
    Distal degeneration of the long descending corticospinal axons of upper motor neurons
    produces spasticity, hyperreflexia and extensor plantar responses in a
    lower-limb-predominant (paraparetic) distribution that eventually generalises to
    tetraparesis — the feature that places this disorder in the hereditary spastic
    paraplegia nomenclature as SPG79B.
  locations:
  - preferred_term: corticospinal tract
    term:
      id: UBERON:0002707
      label: corticospinal tract
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  cell_types:
  - preferred_term: upper motor neuron
    term:
      id: CL:0008048
      label: upper motor neuron
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "upper motor neuron dysfunction. Through homozygosity mapping of the affected "
    explanation: Documents spasticity with upper motor neuron dysfunction in the index family.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features. Recessive, disease causing variants in Ubiquitin C-terminal "
    explanation: >
      Places the disorder within the hereditary spastic paraplegia nomenclature (SPG79) as
      a recessive UCHL1 disorder characterised by spasticity and paraplegia.
  downstream:
  - target: Spastic Paraplegia
    description: Corticospinal degeneration produces lower-limb-predominant spasticity and weakness.
    causal_link_type: DIRECT
  - target: Upper Motor Neuron Dysfunction
    description: Loss of corticospinal input produces upper motor neuron signs.
    causal_link_type: DIRECT
  - target: Tetraparesis
    description: >
      Progressive, generalising corticospinal involvement ultimately produces
      four-limb weakness.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

phenotypes:
- category: Ophthalmologic
  name: Optic Atrophy
  description: >
    Bilateral optic atrophy with childhood onset is the usual presenting feature and the
    ophthalmic hallmark of the disease.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
    onset:
      onset_category: CHILDHOOD
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "siblings developed childhood-onset optic atrophy, followed by spasticity and "
    explanation: Documents childhood-onset optic atrophy as the first manifestation in three affected siblings.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "
    explanation: Lists optic atrophy among the defining features of SPG79.

- category: Ophthalmologic
  name: Progressive Visual Loss
  description: >
    Visual function declines progressively from childhood as retinal ganglion cell and
    optic nerve axon loss accumulates.
  phenotype_term:
    preferred_term: Progressive visual loss
    term:
      id: HP:0000529
      label: Progressive visual loss
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive disease resembling Behr syndrome, starting with visual impairment, "
    explanation: >
      Documents visual impairment as the childhood-onset presenting feature of a slowly
      progressive UCHL1 disease course.

- category: Ophthalmologic
  name: Blindness
  description: >
    Progressive optic neuropathy culminates in blindness, typically during childhood.
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive neurodegenerative syndrome featuring childhood onset blindness, "
    explanation: Childhood-onset blindness is the first-listed defining feature of the syndrome.

- category: Neurologic
  name: Cerebellar Ataxia
  description: >
    Progressive cerebellar ataxia with gait and limb involvement follows the visual loss.
  phenotype_term:
    preferred_term: Cerebellar ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: Cerebellar ataxia is a core component of the defining clinical constellation.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "
    explanation: Independently lists cerebellar signs among the defining features of SPG79.

- category: Neurologic
  name: Nystagmus
  description: >
    Nystagmus reflects combined cerebellar oculomotor dysfunction and early severe visual
    loss.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: Nystagmus is listed among the defining features of the syndrome.

- category: Neurologic
  name: Impaired Proprioception
  description: >
    Dorsal column dysfunction produces loss of joint position sense, contributing a
    sensory component to the ataxia.
  phenotype_term:
    preferred_term: Impaired proprioception
    term:
      id: HP:0010831
      label: Impaired proprioception
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: >
      Dorsal column dysfunction — decreased vibration and position sense — is a defining
      feature of the syndrome.

- category: Neurologic
  name: Impaired Vibratory Sensation
  description: >
    Loss of vibration sense is the other half of the dorsal column syndrome.
  phenotype_term:
    preferred_term: Impaired vibratory sensation
    term:
      id: HP:0002495
      label: Impaired vibratory sensation
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar ataxia, nystagmus, dorsal column dysfuction, and spasticity with "
    explanation: >
      Dorsal column dysfunction, which comprises reduced vibration and position sense, is
      a defining feature of the syndrome.

- category: Neurologic
  name: Spastic Paraplegia
  description: >
    Lower-limb-predominant spasticity and weakness — the feature that gives the disorder
    its SPG79B designation — develops after the visual loss and progresses.
  phenotype_term:
    preferred_term: Spastic paraparesis
    term:
      id: HP:0002313
      label: Spastic paraparesis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity, paraplegia, optic atrophy, cerebellar signs, and other variable "
    explanation: Spasticity and paraplegia are the defining motor features of SPG79.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive spasticity, weakness, and atrophy of the lower legs and ataxia. "
    explanation: Documents progressive lower-limb spasticity, weakness and atrophy in two UCHL1-deletion siblings.

- category: Neurologic
  name: Upper Motor Neuron Dysfunction
  description: >
    Pyramidal signs — spasticity, extensor plantar responses and ankle clonus — reflect
    corticospinal tract degeneration. Importantly, deep tendon reflexes are usually NOT
    brisk in this disease: because a motor neuropathy is superimposed on the pyramidal
    syndrome, reflexes are typically reduced or absent, which can obscure the upper motor
    neuron component on examination.
  phenotype_term:
    preferred_term: Upper motor neuron dysfunction
    term:
      id: HP:0002493
      label: Upper motor neuron dysfunction
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "upper motor neuron dysfunction. Through homozygosity mapping of the affected "
    explanation: Upper motor neuron dysfunction is explicitly part of the defining phenotype.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had marked lower limb spasticity, extensor plantar responses and ankle clonus, and a severe scoliosis."
    explanation: >
      Documents the pyramidal examination findings — spasticity, extensor plantars and
      clonus — in a recessive UCHL1 patient.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deep tendon reflexes were absent in the upper and lower limbs"
    explanation: >
      Supports the caveat in the description: reflexes are absent or reduced rather than
      brisk, because of the coexisting peripheral neuropathy. The sibling likewise had
      reflexes "pathologically reduced in upper and lower limbs, and plantar responses
      were extensor".

- category: Neurologic
  name: Loss of Ambulation
  description: >
    Loss of independent ambulation is the dominant functional outcome of the disease and
    is recorded in every one of the ten patients reported across the four published
    SPG79B families. In the two most recently reported siblings the transition to
    non-ambulance was precipitated by an intercurrent event — a femoral fracture in one
    and corrective foot surgery in the other — on a background of progressive spasticity,
    weakness and foot deformity, so the age at loss of walking is variable (8 to 38 years
    in that family) even though the endpoint is near-universal.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Loss of ambulation
    term:
      id: HP:0002505
      label: Loss of ambulation
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs + + + + + + + + + + Lost ambulation + + + + + + + + + + Seizures − − + − − − + − − −"
    explanation: >
      The "Lost ambulation" row of Table 1, which tabulates all ten patients reported
      across the four published SPG79B families, is positive ("+") for every patient.
      This 10/10 denominator counts loss of ambulation specifically and is the basis for
      the VERY_FREQUENT band.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She became non-ambulant following a femoral fracture aged 38 years."
    explanation: >
      Documents loss of ambulation in the index patient, and the intercurrent fracture
      that precipitated it.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He became non-ambulant aged 8 years following surgical correction of his foot deformity."
    explanation: >
      Documents loss of ambulation in the affected sibling at a much earlier age,
      illustrating the wide within-family variability in when walking is lost.

- category: Neurologic
  name: Cognitive Impairment
  description: >
    Cognition is a genuinely variable feature of this disease rather than a uniform one.
    Table 1 of the four-family review scores cognitive impairment as present in 4 of the
    9 assessable patients (one not assessed). Both siblings of the UCHL1-deletion family
    had explicitly normal cognition, and the Rydning family had remarkably preserved
    cognition, which those authors linked to the hyperactive p.Arg178Gln allele (see
    `mechanistic_hypotheses`).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures − − + − − − + − − − Cognitive impairmentNA + + − − − + + − − Facial dysmorphismNANANANANANA + + + +"
    explanation: >
      The "Cognitive impairment" row of Table 1, which tabulates the ten patients
      reported across the four published SPG79B families: one not assessed (NA) and
      4 of the remaining 9 scored positive. That 4/9 (44%) denominator counts cognitive
      impairment specifically and places it in the FREQUENT band (30-79%). Rendered from
      the source HTML table, so the row runs the label and first cell together.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive function was also unaffected in P2."
    explanation: >
      Counter-evidence recorded deliberately: cognition was explicitly normal in this
      patient (and, stated separately, in the index sibling). Cognitive impairment is
      therefore not a universal feature, which is why the band is FREQUENT rather than
      VERY_FREQUENT.

- category: Neurologic
  name: Seizures
  description: >
    Seizures occur in a small minority of patients (2 of the 10 in the published SPG79B
    series) and were a presenting feature, together with developmental delay, in one
    child of the Indian family.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lost ambulation + + + + + + + + + + Seizures − − + − − − + − − − Cognitive impairmentNA + + − − − + + − −"
    explanation: >
      The "Seizures" row of Table 1, covering all ten patients reported across the four
      published SPG79B families: 2 positive of 10 (20%). That denominator counts seizures
      specifically and places them in the OCCASIONAL band (5-29%).
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional, less consistently described features include epilepsy, cognitive impairment, facial myokymia, fasciculations, and reduced peripheral sensation, reflecting the widespread expression of UCHL1 in most neuronal cells."
    explanation: >
      Independently confirms epilepsy as a real but inconsistent feature of SPG79. This
      is an aggregate sentence covering several features, so it supports the
      disease-phenotype association only; the OCCASIONAL band rests on the Table 1
      seizure row above.

- category: Musculoskeletal
  name: Foot Deformity
  description: >
    Distal denervation produces equinovarus and pes cavus foot deformity, which in one
    family was severe enough to make nerve conduction studies technically impossible.
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  notes: >
    HPO binding uses Pes cavus as the closest available term. The deformity documented in
    the cited family is equinovarus; pes cavus is separately recorded in Table 1 for
    patients of two of the four published families.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented with distal upper and lower limb wasting and equinovarus deformity due to peripheral neuropathy and spastic paraparesis"
    explanation: >
      Documents equinovarus foot deformity attributed to the combined neuropathy and
      spastic paraparesis. Scored PARTIAL because the quoted deformity is equinovarus
      rather than the pes cavus the HPO term names.

- category: Craniofacial
  name: Facial Dysmorphism
  description: >
    A recognisable facial appearance — low nasal bridge, micrognathia and large, low-set
    ears — was present in all four patients of the two most recently reported families.
    It is not part of the original syndrome description and was not assessed in the
    earlier families, so it should be treated as a candidate rather than established
    feature.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she had facial dysmorphism including low nasal bridge, micrognathia, and large, low-set ears"
    explanation: >
      Documents the specific dysmorphic features; the sibling had the same triad plus
      facial hypotonia.

- category: Ophthalmologic
  name: Ophthalmoparesis
  description: >
    Ophthalmoparesis is reported in a minority of patients and is one of the features
    that historically aligned this presentation with Behr syndrome.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ophthalmoparesis
    term:
      id: HP:0000597
      label: Ophthalmoparesis
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed bilateral optic atrophy, both pendular and gaze induced nystagmus, ophthalmoparesis, facial dysmorphism"
    explanation: Documents ophthalmoparesis on examination in a recessive UCHL1 patient.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nystagmus + + + + + + + + − + OphthalmoparesisNANANA − + − − − − + Pyramidal signs + + + + + + + + + + Spasticity"
    explanation: >
      The "Ophthalmoparesis" row of Table 1: three patients not assessed (NA) and 2 of
      the remaining 7 positive (29%). That denominator counts ophthalmoparesis
      specifically and places it at the top of the OCCASIONAL band (5-29%). Rendered
      from the source HTML table, so the row label runs into the first cells.

- category: Neurologic
  name: Tetraparesis
  description: >
    The motor deficit generalises from the lower limbs to all four limbs in the late
    stage of the disease, as reflected in the Orphanet/MONDO clinical definition of the
    entity.
  phenotype_term:
    preferred_term: Tetraparesis
    term:
      id: HP:0002273
      label: Tetraparesis
    clinical_course: PROGRESSIVE
  notes: >
    Progression to tetraparesis is stated in the Orphanet/MONDO clinical definition of
    this entity (Orphanet:352654 / MONDO:0014209). No abstract-level quotable
    primary-literature statement of tetraparesis was found, so this phenotype is recorded
    without an evidence item rather than with a fabricated snippet, per the project SOP on
    unverifiable claims.

- category: Neurologic
  name: Peripheral Neuropathy
  description: >
    A peripheral motor (and in some patients sensorimotor) axonal neuropathy is a
    near-constant feature of the recessive disease, present in every one of the ten
    patients reported across the four published SPG79B families. It contributes distal
    upper- and lower-limb wasting, equinovarus/pes cavus foot deformity, and — because it
    is superimposed on the pyramidal syndrome — deep tendon reflexes that are typically
    reduced or absent rather than brisk.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both siblings presented in childhood with motor developmental delay, optic atrophy leading to progressive visual loss, cerebellar ataxia, spastic paraparesis, and motor neuropathy."
    explanation: >
      Documents motor neuropathy as part of the childhood-onset presentation in the
      recessive UCHL1-deletion siblings.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "there was length-dependent atrophy and sensory loss in-keeping with a peripheral neuropathy"
    explanation: >
      Documents the length-dependent atrophy and sensory loss on examination that define
      the clinical peripheral neuropathy, supporting the length-dependent dying-back
      mechanism curated in `pathophysiology`.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to spasticity, ataxia, and peripheral neuropathy, SPG79 is characterized by severe optic atrophy in the first decade of life."
    explanation: >
      Peripheral neuropathy is named as a defining component of SPG79 alongside
      spasticity, ataxia and optic atrophy. This is an aggregate statement, so it
      supports the disease-phenotype association only; the frequency band rests on the
      Table 1 row below.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pyramidal signs + + + + + + + + + + Spasticity + + + − + + + + + + Peripheral motor neuropathy + + + + + + + + + + Pes cavus"
    explanation: >
      The "Peripheral motor neuropathy" row of Table 1, covering all ten patients
      reported across the four published SPG79B families, is positive for every patient.
      That 10/10 denominator counts peripheral motor neuropathy specifically and is the
      basis for the VERY_FREQUENT band.
  - reference: PMID:35986737
    reference_title: Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented with spasticity (24/31), ataxia (28/31), neuropathy (11/21), and optic "
    explanation: >
      Scored PARTIAL and cross-arm: this quantified neuropathy frequency comes from the
      allelic autosomal dominant (SPG79A) cohort, not from the recessive SPG79B families.
      Included only to show that neuropathy recurs across the whole UCHL1 allelic
      spectrum; it does not support the recessive frequency band.

- category: Musculoskeletal
  name: Scoliosis
  description: >
    Scoliosis developed in both siblings of the UCHL1-deletion family and led to
    restrictive respiratory compromise, making spinal surveillance clinically relevant.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "also developed scoliosis, leading to respiratory problems. In their late 30's, "
    explanation: Documents scoliosis with consequent respiratory problems in two siblings with a homozygous UCHL1 deletion.

- category: Respiratory
  name: Nocturnal Hypoventilation
  description: >
    Restrictive respiratory compromise, driven by the severe scoliosis and progressive
    weakness, produced nocturnal hypoventilation requiring overnight non-invasive
    ventilation from the age of 39 in the index patient. Reported in one family, so it
    is a recognised complication of the advanced disease rather than an established
    universal feature.
  phenotype_term:
    preferred_term: Nocturnal hypoventilation
    term:
      id: HP:0002877
      label: Nocturnal hypoventilation
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From the age of 39, she developed nocturnal hypoventilation and was commenced on overnight non-invasive ventilation."
    explanation: >
      Documents nocturnal hypoventilation and the initiation of overnight non-invasive
      ventilation in a recessive UCHL1 patient.

- category: Cardiovascular
  name: Hypertrophic Cardiomyopathy
  description: >
    Hypertrophic cardiomyopathy developed in adulthood in both siblings of the
    UCHL1-deletion family and caused sudden cardiac death in each. This is a proposed
    rather than established component of the syndrome — reported in a single family — but
    it is the basis for recommending cardiac surveillance.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "possibility that hypertrophic cardiomyopathy may be an additional feature of the "
    explanation: >
      Scored PARTIAL because the authors themselves frame hypertrophic cardiomyopathy as a
      possible additional feature based on a single family, not an established one.

- category: Cardiovascular
  name: Sudden Cardiac Death
  description: >
    Both reported siblings with the homozygous UCHL1 in-frame deletion died suddenly of
    cardiac causes in their fifth decade, in the setting of hypertrophic cardiomyopathy.
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
    onset:
      onset_category: MIDDLE_AGE
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac "
    explanation: Documents sudden cardiac death in both affected siblings.

genetic:
- name: UCHL1
  notes: >
    Biallelic pathogenic variants in UCHL1 (chromosome 4p13) are the sole established
    cause of this entity. UCHL1 encodes ubiquitin C-terminal hydrolase L1 (UCH-L1, also
    known as PGP 9.5), a neuron-specific deubiquitinating enzyme. Only a small number of
    families have been reported. Heterozygous UCHL1 loss-of-function causes a distinct,
    later-onset autosomal dominant disorder (SPG79A) — see `notes` and
    `differential_diagnoses`.
  gene_term:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "binding domain of UCHL1 (UCHL1(GLU7ALA)), shared by all affected subjects. As "
    explanation: >
      Establishes the homozygous UCHL1 p.Glu7Ala variant, shared by all affected members
      of the index family, as the cause of the syndrome.
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UCHL1, c.533G > A (p.Arg178Gln) and c.647C > A (p.Ala216Asp), cosegregating with "
    explanation: Independent confirmation in a second family with compound heterozygous UCHL1 variants cosegregating with the phenotype.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hydrolase-L1 (UCHL1) gene have been implicated as a cause for SPG79 in two "
    explanation: A third independent family, establishing UCHL1 as the SPG79 gene.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1."
    explanation: A fourth family, with a homozygous in-frame single-codon deletion in UCHL1.

variants:
- name: UCHL1 p.Glu7Ala
  description: >
    The index homozygous missense allele (consanguineous family). Glu7 lies within the
    ubiquitin-binding region; the substitution reduces ubiquitin affinity at least
    sevenfold, near-completely abolishes hydrolase activity, and is predicted to obstruct
    correct positioning of the substrate for tunnelling beneath the cross-over loop
    spanning the catalytic cleft, giving a >100-fold loss of catalytic efficiency.
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "resulted in a >100-fold reduction in the efficiency of UCHL1(GLU7ALA) relative "
    explanation: Quantifies the catalytic consequence of the index disease allele.

- name: UCHL1 p.Ala216Asp
  description: >
    A compound-heterozygous missense allele that renders the recombinant protein insoluble
    — a straightforward loss-of-function mechanism.
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "consequences as the insoluble Ala216Asp variant leads to loss of function, "
    explanation: Documents insolubility and consequent loss of function for this allele.

- name: UCHL1 p.Arg178Gln
  description: >
    A compound-heterozygous missense allele with a counter-intuitive functional
    consequence: purified recombinant p.Arg178Gln protein shows roughly four-fold
    increased hydrolytic activity, because Arg178 normally holds the catalytic histidine
    in a partially inactive arrangement. Later biophysical work attributed the gain to a
    kcat effect and a more reactive catalytic cysteine, with widespread changes in protein
    dynamics rather than a rearranged active site.
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ubiquitin hydrolase assays showed a 4-fold increased hydrolytic activity of the "
    explanation: Documents the increased catalytic activity of this disease allele.
  - reference: PMID:38185323
    reference_title: Altered Protein Dynamics and a More Reactive Catalytic Cysteine in a Neurodegeneration-associated UCHL1 Mutant.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Enzyme kinetics show the activation is due to a kcat effect despite a slightly "
    explanation: Provides the structural/kinetic basis of the activating effect of p.Arg178Gln.

- name: UCHL1 c.459+2T>C
  description: >
    A novel homozygous canonical splice-donor variant identified by whole-exome sequencing
    in an Indian family with two affected siblings and validated by Sanger sequencing.
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gene (NM_004181.4: c.459+2T>C). The variant was identified by "
    explanation: Reports the homozygous splice-site allele in a third SPG79 family.

- name: UCHL1 p.Gly210del
  description: >
    A novel homozygous in-frame single-codon deletion (c.627_629del) identified in two
    siblings with a Behr-syndrome-like presentation who additionally developed
    hypertrophic cardiomyopathy.
  gene:
    preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1."
    explanation: Reports the in-frame deletion allele in a fourth family.

diagnosis:
- name: Molecular Genetic Testing
  description: >
    Diagnosis rests on identifying biallelic pathogenic UCHL1 variants. Because the
    clinical picture (optic atrophy plus spastic ataxia) is shared by many genetically
    distinct disorders, exome/genome sequencing or a broad hereditary-spastic-paraplegia,
    hereditary-ataxia or inherited-optic-neuropathy gene panel — rather than single-gene
    testing — is the appropriate first-line approach.
  evidence:
  - reference: PMID:23359680
    reference_title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals followed by whole-exome sequencing of the index case, we identified "
    explanation: The disease gene was, and continues to be, identified by exome sequencing.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosis is based on gene panel testing or whole-exome/genome sequencing."
    explanation: States that molecular diagnosis in this clinically defined group rests on panel or exome/genome sequencing.

- name: Ophthalmological assessment
  description: >
    Fundoscopy, visual acuity and visual-field testing, optical coherence tomography and
    visual evoked potentials document the optic neuropathy. Because optic atrophy can be
    asymptomatic and under-recognised, the optic nerves should be assessed deliberately in
    anyone presenting with ataxia and spasticity.
  results: Bilateral optic disc pallor with reduced acuity.
  evidence:
  - reference: PMID:42375238
    reference_title: "UCHL1-Related Dominant Optic Atrophy: Report of Two New Families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinicians should carefully assess the optic nerves in individuals "
    explanation: >
      Explicit clinical recommendation to examine the optic nerves in patients presenting
      with ataxia and spasticity, since optic atrophy can be asymptomatic and
      under-reported yet is decisive for directing genomic testing in UCHL1 disease.
      (Reported for the allelic dominant disorder; the assessment recommendation applies
      across UCHL1-related disease.)

- name: Metabolic and CSF workup (exclusion)
  description: >
    There is no diagnostic biochemical test for this disease; metabolic and CSF studies
    serve to exclude the treatable and mitochondrial mimics that the optic-atrophy-plus
    presentation raises. In the recessive UCHL1 family a detailed panel — acylcarnitines,
    urinary organic acids, very long chain fatty acids, pristanic and phytanic acids,
    lysosomal enzymes, copper, caeruloplasmin and acanthocytes — was entirely normal, as
    were CSF constituents. A normal workup of this kind therefore supports, rather than
    argues against, a UCHL1 diagnosis.
  results: Normal metabolic panel and normal CSF constituents.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Detailed laboratory work-up (including acylcarnitines, urinary organic acids, very long chain fatty acids, pristanic and phytanic acids, lysosomal enzymes, copper, caeruloplasmin, and acanthocytes) was normal. CSF constituents were normal in both cases."
    explanation: >
      Documents the exclusion panel and its normal result in molecularly confirmed
      recessive UCHL1 disease.

- name: Nerve conduction studies and electrophysiology
  description: >
    Nerve conduction studies and EMG are used to characterise the peripheral neuropathy.
    A practical caveat is recorded in the literature: in advanced disease the foot
    deformity and swelling may make neurophysiological testing technically impossible, so
    a negative or absent study should not be read as excluding neuropathy.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unfortunately, neurophysiological testing was not technically possible due to the degree of foot deformity and swelling."
    explanation: >
      Scored PARTIAL: this documents a limitation of electrophysiology in advanced
      disease rather than a positive diagnostic yield. It is curated because the
      practical caveat matters when interpreting a missing study.

- name: Cardiac surveillance
  description: >
    Echocardiographic and rhythm surveillance is recommended in UCHL1-related
    neurodegeneration because hypertrophic cardiomyopathy with sudden cardiac death has
    been reported.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "highlights the importance of cardiac follow-up and treatment in "
    explanation: Directly recommends cardiac follow-up in UCHL1-associated neurodegeneration.

treatments:
- name: Supportive and Multidisciplinary Care
  description: >
    No disease-modifying therapy exists. Management is supportive and multidisciplinary:
    low-vision rehabilitation, physiotherapy and spasticity management, mobility aids,
    orthopaedic assessment of scoliosis, respiratory monitoring, cardiac surveillance and
    genetic counselling.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  notes: >
    `therapeutic_modality` is deliberately omitted: this bundle spans behavioural,
    procedural (cardiac and orthopaedic surveillance) and pharmacological components, so
    no single platform value applies. Per CLAUDE.md, generic action terms such as
    NCIT:C15747 are excluded from mechanical modality backfill.

- name: Low-Vision Rehabilitation
  description: >
    Visual aids, educational support and low-vision rehabilitation for the early, severe
    and ultimately profound visual impairment.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  therapeutic_modality: BEHAVIORAL

- name: Physical Therapy for Spasticity and Ataxia
  description: >
    Physiotherapy, stretching, orthoses and gait training to manage progressive spasticity,
    ataxia and contracture risk.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  therapeutic_modality: BEHAVIORAL

- name: Antispasticity Pharmacotherapy
  description: >
    Symptomatic spasticity management is extrapolated from general hereditary spastic
    paraplegia practice rather than from any UCHL1-specific study: oral baclofen or
    tizanidine, focal botulinum toxin, and intrathecal baclofen in severe generalised
    spasticity. No UCHL1-specific response rate or adverse-event estimate exists, and
    symptomatic measures in hereditary spastic paraplegia as a class remain
    unsatisfactory.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
    - preferred_term: tizanidine
      term:
        id: CHEBI:63629
        label: tizanidine
    - preferred_term: botulinum toxin (no CHEBI/NCIT chemical-entity term available)
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:35163618
    reference_title: "Hereditary Spastic Paraplegia: An Update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Though modern medical interventions help recognize and manage the "
    explanation: >
      Scored PARTIAL and explicitly class-extrapolated: this hereditary spastic paraplegia
      review supports symptomatic management for the HSP class as a whole (and notes that
      symptomatic measures remain below satisfaction), not UCHL1/SPG79B-specific efficacy.

- name: Cardiac Surveillance and Management
  description: >
    Given the report of hypertrophic cardiomyopathy causing sudden cardiac death in both
    affected siblings of one family, cardiac follow-up and treatment are recommended in
    UCHL1-related neurodegeneration.
  treatment_term:
    preferred_term: therapeutic procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "highlights the importance of cardiac follow-up and treatment in "
    explanation: Directly supports cardiac follow-up and treatment as part of management.
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Given the symptomatic features of a possible mitochondrial disorder, in particular optic atrophy, a cardiac evaluation was carried out in both patients."
    explanation: >
      Documents echocardiographic cardiac evaluation as the surveillance modality that
      detected the cardiomyopathy in this family.

- name: Heart Failure Pharmacotherapy for UCHL1-Associated Cardiomyopathy
  description: >
    Both affected siblings of the UCHL1-deletion family were treated with ACE inhibitors
    and beta-blockers, and their cardiac function stabilised. This is standard
    cardiomyopathy therapy rather than a disease-specific intervention, and it did not
    prevent eventual sudden cardiac death in either patient — an important limitation to
    convey when counselling.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
    - preferred_term: beta-blocker
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both siblings were commenced on ACE inhibitors and beta-blockers and their cardiac function stabilized."
    explanation: >
      Documents the agents used and the short-term stabilisation of cardiac function.
      Scored PARTIAL because this is an uncontrolled two-patient observation, and the
      same source records that both siblings nonetheless died of sudden cardiac death.

- name: Non-Invasive Ventilation
  description: >
    Overnight non-invasive ventilation for the nocturnal hypoventilation that follows
    scoliosis-related restrictive respiratory compromise in advanced disease. NCIT has no
    clinical-action term for non-invasive ventilation reachable from Clinical Intervention
    or Procedure, so the generic therapeutic-procedure term is used and the specificity is
    carried in the name and description.
  treatment_term:
    preferred_term: non-invasive ventilation
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  therapeutic_modality: DEVICE
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she developed nocturnal hypoventilation and was commenced on overnight non-invasive ventilation."
    explanation: Documents initiation of overnight non-invasive ventilation in a recessive UCHL1 patient.

- name: Scoliosis Surgery
  description: >
    Severe progressive scoliosis may require spinal surgery; it was performed at age 16
    in the index patient of the UCHL1-deletion family, whose scoliosis later contributed
    to restrictive respiratory compromise.
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she developed progressive lower limb spasticity, foot deformities, and severe scoliosis requiring spinal surgery aged 16 years"
    explanation: Documents spinal surgery for severe scoliosis in a recessive UCHL1 patient.

- name: Genetic Counseling
  description: >
    Autosomal recessive inheritance carries a 25% recurrence risk for siblings; carrier
    testing and reproductive counselling should be offered. Counselling should also
    address the distinct autosomal dominant disorder caused by heterozygous UCHL1
    loss-of-function (SPG79A), which may be relevant to the wider family.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling

animal_models:
- species: Mus musculus
  genotype: Uchl1(gad) - spontaneous in-frame deletion of Uchl1 exons 7-8
  description: >
    The gracile axonal dystrophy (gad) mouse is the reference animal model. It is an
    autosomal recessive spontaneous mutant carrying an in-frame deletion of Uchl1 exons 7
    and 8 that removes a 42-amino-acid segment containing a catalytic residue. gad mice
    show early sensory ataxia followed by motor ataxia and posterior paralysis, with
    dying-back axonal degeneration, terminal spheroid bodies, and retrograde accumulation
    of ubiquitin-positive deposits along sensory and motor pathways — closely paralleling
    the human dorsal-column-plus-corticospinal phenotype.
  genes:
  - preferred_term: UCHL1
    term:
      id: hgnc:12513
      label: UCHL1
  evidence:
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we find that the gad mutation is caused by an in-frame deletion "
    explanation: Establishes the Uchl1 lesion underlying the gad mouse.
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "shows sensory ataxia at an early stage, followed by motor ataxia at a later "
    explanation: >
      The temporal sequence in the model — sensory (dorsal column) involvement preceding
      motor involvement — mirrors the human disease course.
  - reference: PMID:11555633
    reference_title: Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "display sensory ataxia followed by posterior paralysis and "
    explanation: >
      Independently characterises the gad phenotype and shows that concurrent Uch-L3 loss
      worsens it, indicating partial functional redundancy among UCH isozymes.

differential_diagnoses:
- name: Behr syndrome
  description: >
    Behr syndrome is the closest clinical mimic and the most important
    named-entity-confusion hazard for this disorder: it is defined by essentially the same
    constellation of early-onset optic atrophy, ataxia, pyramidal signs, posterior-column
    sensory loss and peripheral neuropathy. It is, however, a clinically defined,
    genetically heterogeneous mitochondrial entity, with biallelic OPA1 as its core
    molecularly resolved cause and OPA3, C12orf65/MTRFR and C19orf12 as additional causes,
    all converging on impaired mitochondrial bioenergetics. UCHL1 disease reaches the same
    clinical picture by an entirely different route — failure of the neuronal
    ubiquitin-proteasome system. Indeed one UCHL1 family was published under the Behr
    syndrome label as a novel genetic form of Behr syndrome, so the two entities are
    curated separately in dismech (`Behr_Syndrome`) and the boundary is molecular, not
    clinical.
  disease_term:
    preferred_term: Behr syndrome
    term:
      id: MONDO:0008858
      label: Behr syndrome
  distinguishing_features:
  - Mitochondrial bioenergetic mechanism (OPA1, OPA3, C12orf65/MTRFR, C19orf12) rather than ubiquitin-proteasome failure
  - Elevated blood or CSF lactate and a lactate peak on MR spectroscopy
  - Leigh-like basal-ganglia signal abnormality on MRI
  - Cytochrome-c-oxidase-deficient fibres on muscle biopsy
  - Multiple mitochondrial DNA deletions in skeletal muscle
  - Molecular testing is the definitive discriminator
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behr syndrome is a clinically distinct, but genetically "
    explanation: >
      States that Behr syndrome is clinically distinct but genetically heterogeneous — the
      reason a UCHL1 family could be reported under that label, and the reason the
      boundary between the two dismech entries must be drawn molecularly.

- name: SPG79A - autosomal dominant UCHL1-related spastic ataxia
  disease_term:
    preferred_term: spastic paraplegia 79A, autosomal dominant, with ataxia
    term:
      id: MONDO:0859363
      label: spastic paraplegia 79A, autosomal dominant, with ataxia
  description: >
    The allelic autosomal dominant disorder caused by heterozygous UCHL1 loss of function,
    established by gene-burden analysis across 3169 ataxia and spastic-paraplegia patients
    and 33,141 controls, with 34 cases from 18 families. It presents later (adult or
    late-onset), is milder, and shows spasticity, ataxia, neuropathy and optic atrophy in
    varying combinations; the mechanism is UCHL1 haploinsufficiency (approximately 50%
    protein reduction in patient fibroblasts) rather than the near-complete loss seen in
    the recessive disease. It is a distinct OMIM and MONDO entity and is not curated here.
  distinguishing_features:
  - Monoallelic (heterozygous) UCHL1 loss-of-function variant
  - Autosomal dominant family history across generations
  - Adult or late-onset course rather than childhood onset
  - Milder and more variable phenotype, with optic atrophy sometimes asymptomatic
  - Approximately 50% UCHL1 protein reduction rather than near-complete loss of function
  evidence:
  - reference: PMID:35986737
    reference_title: Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and functional studies established haploinsufficiency of UCHL1 as a novel "
    explanation: Establishes heterozygous UCHL1 haploinsufficiency as a separate, dominant disease mechanism.
  - reference: PMID:39030458
    reference_title: "Phenotypic variability related to dominant UCHL1 mutations: about three families with optic atrophy and ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a severe, complex autosomal recessive spastic paraplegia (HSP79) [1] [2] "
    explanation: >
      Explicitly contrasts the severe complex autosomal recessive UCHL1 disorder (this
      entry) with the more recently described dominant UCHL1 disease.

- name: Hereditary spastic paraplegia - other genetic forms
  description: >
    Because spastic paraplegia is a defining feature, the broader hereditary spastic
    paraplegia group — in particular the complex/complicated forms that combine pyramidal
    signs with optic atrophy, ataxia or neuropathy, such as SPG7 (paraplegin),
    AFG3L2, SPG11 (spatacsin) and MFN2 — must be considered. Most of those combine
    spasticity or neuropathy with optic atrophy through mitochondrial mechanisms, whereas
    UCHL1 disease is a neuronal ubiquitin/proteostasis disorder. Other frequently listed
    phenocopies include OPA1, WFS1, SACS, KIF1A, CAPN1, FDXR, PNPT1, Friedreich ataxia,
    and the treatable metabolic spastic paraplegias. dismech curates the group entry
    `Hereditary_Spastic_Paraplegia`; this disorder is SPG79B within that nomenclature but
    is curated as a separate entity because its ubiquitin-proteasome mechanism and its
    optic-atrophy-first natural history are distinctive.
  disease_term:
    preferred_term: hereditary spastic paraplegia
    term:
      id: MONDO:0019064
      label: hereditary spastic paraplegia
  distinguishing_features:
  - Optic atrophy preceding the motor syndrome
  - Prominent dorsal-column sensory loss with impaired vibration and position sense
  - Biallelic UCHL1 variants on sequencing
  evidence:
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spastic Paraplegia-79 (SPG79) is an autosomal recessive type of childhood onset "
    explanation: Places this disorder within the hereditary spastic paraplegia nomenclature as SPG79.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >
    Ultra-rare, and reported only as individual kindreds. As of 2020 only four families
    (ten patients) had been described worldwide. A qualitative band is used rather than a
    numeric Orphanet class because no source gives a numeric rate — Orphanet
    (ORPHA:352654) lists the entity without a documented prevalence figure.
  evidence:
  - reference: PMID:32656641
    reference_title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, mutations in UCHL1 have been described in only three families"
    explanation: >
      At the time of this fourth report only three families had previously been
      published worldwide, supporting the ultra-rare, cases-in-literature band.
  - reference: PMID:29735986
    reference_title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hydrolase-L1 (UCHL1) gene have been implicated as a cause for SPG79 in two "
    explanation: >
      At the time of this third report only two families had been published worldwide,
      an independent snapshot of the same ultra-rare occurrence.

classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  mechanistic_category:
  - classification_value: proteotoxic disease

mechanistic_hypotheses:
- hypothesis_group_id: uchl1_activity_window
  hypothesis_label: >
    Neurodegeneration results from departure from an optimal window of UCH-L1 activity in
    either direction, not simply from reduced hydrolase activity
  status: EMERGING
  description: >
    The p.Glu7Ala, p.Ala216Asp, splice-site and in-frame-deletion alleles all reduce
    UCH-L1 function, which supports a straightforward loss-of-function model. The
    p.Arg178Gln allele, however, has roughly four-fold increased hydrolytic activity in
    vitro, and later biophysical work confirmed a genuine kcat gain with a more reactive
    catalytic cysteine. Two non-exclusive reconciliations are on the table: (i) that the
    unifying lesion is reduced steady-state UCH-L1 protein rather than specific activity,
    consistent with the roughly four-fold lower total UCHL1 measured in patient
    fibroblasts; and (ii) that both hypoactive and hyperactive enzyme perturb ubiquitin
    homeostasis, implying an optimal activity window. The original authors additionally
    propose that the increased activity of p.Arg178Gln may be protective for cognition,
    which is remarkably preserved in those patients. A third, independent line of evidence
    pushes in the same direction: a catalytically dead UCHL1 C90A knock-in mouse does NOT
    reproduce the sensory/motor deficits, gracile-tract degeneration or premature death of
    UCHL1-deficient mice, implying that loss of hydrolase activity alone is not sufficient
    for the neurodegenerative phenotype and that non-hydrolase UCH-L1 functions (ubiquitin
    stabilisation, ubiquitin ligation, cytoskeletal interaction) matter. Which model is
    correct is unresolved.
  evidence:
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "identified missense variants reveal surprisingly different functional "
    explanation: >
      States directly that the two disease alleles in one patient have opposite functional
      consequences — the observation the hypothesis is built on.
  - reference: PMID:28007905
    reference_title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "activity of the Arg178Gln variant offers a protective effect on cognitive "
    explanation: The authors' own proposed reconciliation — increased activity as cognitively protective.
  - reference: PMID:38185323
    reference_title: Altered Protein Dynamics and a More Reactive Catalytic Cysteine in a Neurodegeneration-associated UCHL1 Mutant.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "showed higher catalytic activity than "
    explanation: Independently confirms and structurally explains the gain of catalytic activity in the p.Arg178Gln disease allele.
  - reference: PMID:33159930
    reference_title: Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The C90A mouse did not develop the sensory and motor deficits, degeneration of the "
    explanation: >
      A catalytically dead knock-in mouse does not phenocopy UCHL1 deficiency, arguing
      that loss of hydrolase activity per se is not the whole mechanism — direct support
      for the view that the disease is not simply "less catalysis". Model-organism
      evidence.
  - reference: PMID:33159930
    reference_title: Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "that the hydrolase activity of UCHL1 does not "
    explanation: >
      The authors' explicit conclusion that hydrolase activity does not account for the
      progressive neurodegeneration seen in mice lacking full-length UCHL1.

discussions:
- discussion_id: uchl1_human_neuropathology_gap
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Dying-Back Axonal Degeneration
  - pathophysiology#Cerebellar Degeneration
  prompt: >
    Does the dying-back axonal degeneration with terminal spheroid formation documented in
    the Uchl1-mutant gad mouse actually describe the neuropathology of human biallelic
    UCHL1 disease, and are Purkinje cells the principal cerebellar target in patients?
  rationale: >
    The cellular mechanism curated here — dying-back axonopathy, terminal spheroids,
    retrograde ubiquitin-positive deposits, monoubiquitin depletion — rests almost entirely
    on the gad mouse. No human post-mortem neuropathological series of biallelic UCHL1
    disease is available, and the very small number of reported families means the
    cellular lesion in patients is inferred rather than observed. The cerebellar node is
    additionally inferred from the conserved Purkinje-degeneration module rather than from
    UCHL1-specific human tissue. The mismatch matters because it is the mechanistic link
    from a proteostasis defect to selective long-tract vulnerability, and because mouse
    Uchl1 loss is partly compensated by Uch-L3, a redundancy whose human equivalence is
    unknown.
  proposed_experiments:
  - experiment_id: exp_uchl1_human_neuropathology
    name: Human neuropathological characterisation of biallelic UCHL1 disease
    description: >
      Post-mortem examination of optic nerve, cerebellum, dorsal columns and corticospinal
      tracts in biallelic UCHL1 patients, assessing axonal spheroids, ubiquitin-conjugate
      accumulation, free-monoubiquitin levels and Purkinje-cell counts against
      age-matched controls.
  - experiment_id: exp_uchl1_ipsc_neurons
    name: Patient iPSC-derived neuron modelling
    description: >
      Generate iPSC-derived retinal ganglion cells, cortical projection neurons and
      cerebellar neurons from patients carrying each allele class (p.Glu7Ala hypoactive,
      p.Arg178Gln hyperactive, null), and measure free-ubiquitin pool, ubiquitin-conjugate
      accumulation, axonal transport and distal-axon integrity to test the
      activity-window hypothesis in human cells.
  evidence:
  - reference: PMID:10471497
    reference_title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the mutant is characterized by 'dying-back' type axonal "
    explanation: The mouse-only cellular pathology that is the basis of the open translational question.
  - reference: PMID:11555633
    reference_title: Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To assess whether the two hydrolases have redundant function, we generated mice "
    explanation: >
      The Uch-L1/Uch-L3 double-mutant experiment probes functional redundancy among UCH
      isozymes in mouse, a confounder for translating the model to human disease.

notes: >
  Named-entity-confusion preflight. The MONDO label for this entity
  ("early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome") is
  purely descriptive and names a phenotype cluster shared by many genetically distinct
  diseases, so this entry was built only after independently establishing the causal gene.
  MONDO:0014209 asserts `RO:0004003 HGNC:12513 ! UCHL1`, xrefs OMIM:615491 and
  Orphanet:352654, and carries the synonyms SPG79 and NDGOA; NCBI MedGen (concept
  C3809665) independently defines OMIM 615491 as "Spastic paraplegia-79B (SPG79B) ... an
  autosomal recessive progressive neurologic disorder". The MONDO definition text is
  drawn essentially verbatim from the index UCHL1 report (PMID:23359680). The gene is
  therefore UCHL1 on three independent anchors — the MONDO relationship, the MedGen/OMIM
  definition, and the primary literature. Confusable entities deliberately kept out: Behr
  syndrome (OPA1 and friends), autosomal dominant optic atrophy (OPA1), Friedreich
  ataxia, PLA2G6-related neurodegeneration, and the other hereditary spastic paraplegias.

  Recessive/dominant split. UCHL1 causes two allelic but nosologically separate
  disorders: the severe childhood-onset biallelic disease curated here (SPG79B, OMIM
  615491, MONDO:0014209) and a later-onset autosomal dominant spastic ataxia caused by
  heterozygous loss of function (SPG79A). Reports of the dominant disorder (PMID:35986737,
  PMID:39030458, PMID:41402561, PMID:42375238) are cited here only to characterise the
  allelic spectrum, to distinguish the two entities, to support a general UCH-L1 function
  statement, and — with an explicit PARTIAL/cross-arm caveat — for the neuropathy
  phenotype; they are not used as evidence for the recessive phenotype itself. A separate
  dismech entry for SPG79A would be a reasonable follow-up.

  PARK5 / UCHL1 parkinsonism kept out. A third, older UCHL1 literature — the
  p.Ile93Met (PARK5) dominant-parkinsonism allele and the p.Ser18Tyr protective
  polymorphism — concerns a proposed toxic gain-of-function mechanism and a susceptibility
  association, not the loss-of-function optic-atrophy/spastic-paraplegia spectrum. It is
  deliberately excluded from this entry so that the three UCHL1 disease concepts
  (recessive SPG79B, dominant SPG79A, PARK5) are not merged.

  Behr syndrome boundary. dismech already curates `Behr_Syndrome` (MONDO:0008858) as the
  clinically defined, genetically heterogeneous mitochondrial optic-atrophy-plus entity
  (OPA1 core, plus OPA3, C12orf65/MTRFR, C19orf12). The clinical overlap with UCHL1
  disease is near-complete, and PMID:32656641 in fact reported a UCHL1 family as a novel
  genetic form of Behr syndrome. The two are kept as separate dismech entries because
  their pathophysiology graphs are disjoint — mitochondrial fusion/cristae/OXPHOS failure
  versus ubiquitin-proteasome failure — and because MONDO gives them distinct identifiers.
  UCHL1 is deliberately not added to the `Behr_Syndrome` gene list; the relationship is
  recorded here as a differential diagnosis instead.

  GeneReviews. PubMed searches for a GeneReviews chapter covering UCHL1 or SPG79 returned
  no results (searched 2026-08-01), so no GeneReviews phenotype baseline was available for
  this entry. The phenotype set is therefore built from the four published recessive
  families, principally Table 1 of PMID:32656641, which pools all ten reported patients.
  The class-level chapter PMID:20301682 (Uncomplicated (Pure) Hereditary Spastic
  Paraplegia Overview) is tagged in `references:` as the nearest GeneReviews anchor, but
  with an explicit scope caveat: it covers *pure* HSP, while SPG79B is a complicated HSP,
  so no clinical claim in this entry is drawn from it.

  Deep research provenance. An Edison (falcon) deep-research run was performed and read
  (`research/UCHL1-Related_Neurodegeneration_with_Optic_Atrophy_and_Spastic_Paraplegia-deep-research-falcon.md`,
  33 citations, 12.5 min). Its NEC check was clean — the report is UCHL1-centred
  throughout, names MONDO:0014209 and Orphanet:352654 correctly, and mentions OPA1 only
  as a differential diagnosis. It was used as leads, not ground truth: every PMID it
  suggested was re-fetched with `just fetch-reference` and every snippet verified against
  the cached abstract. Its citation keys are author-year strings rather than PMIDs, so
  each source was independently resolved via PubMed/DOI before use. Two of its leads
  could not be used for evidence: the Genc 2019 mouse-model review (PMID:31394733), whose
  UCHL1(nm3419) corticospinal-neuron claims live in the full text and are absent from the
  cached abstract, and the Drosophila dUCH knockdown work, which models dopaminergic
  rather than optic/spastic degeneration. Its Open Targets-derived claim that the
  dominant paper is `10.1016/j.gim.2023.100961` was not adopted; the verified record used
  here is PMID:35986737 (`10.1016/j.gim.2022.07.006`).

  Evidence discipline: frequency bands. Every `frequency:` value in this entry is derived
  from one source and one source only — Table 1 of PMID:32656641, which pools all ten
  patients reported across the four published SPG79B families and scores each feature
  per patient. Five phenotypes carry a band, and in each case the cited snippet is the
  Table 1 row for *that specific feature*, so the denominator counts the feature the band
  is attached to rather than an aggregate category containing it:

  - Peripheral neuropathy, VERY_FREQUENT — "Peripheral motor neuropathy" row, 10/10.
  - Loss of ambulation, VERY_FREQUENT — "Lost ambulation" row, 10/10.
  - Cognitive impairment, FREQUENT — "Cognitive impairment" row, 4 of 9 assessable (44%),
    one patient not assessed. Counter-evidence (normal cognition in both index siblings)
    is recorded as a REFUTE item on the same phenotype.
  - Seizures, OCCASIONAL — "Seizures" row, 2/10 (20%).
  - Ophthalmoparesis, OCCASIONAL — "Ophthalmoparesis" row, 2 of 7 assessable (29%).

  Bands are deliberately NOT assigned to any other phenotype. Where the only available
  statement is an aggregate one (for example "less consistently described features
  include epilepsy, cognitive impairment, facial myokymia..."), it is retained as
  association evidence with an explicit note that it does not carry the band. The one
  quantified series elsewhere in the literature (optic atrophy 9/17, neuropathy 11/21)
  belongs to the *dominant* SPG79A cohort, is marked PARTIAL and cross-arm, and is never
  used to set a band here. Two Table 1 snippets reproduce a row rendered from the source
  HTML table, so the row label runs into its first cells ("Cognitive impairmentNA...",
  "OphthalmoparesisNANANA...") — that is the source text, not a transcription error.

  `Tetraparesis` is recorded from the Orphanet/MONDO definition with an explanatory
  `notes` field and no evidence item, rather than with an unverifiable snippet.

references:
- reference: PMID:23359680
  title: Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
  findings:
  - statement: >-
      The index report defines the entity: three siblings of a consanguineous union with
      childhood-onset blindness, cerebellar ataxia, nystagmus, dorsal column dysfunction
      and spasticity with upper motor neuron dysfunction, homozygous for UCHL1 p.Glu7Ala.
    supporting_text: "progressive neurodegenerative syndrome featuring childhood onset blindness, "
  - statement: >-
      The disease allele combines loss of ubiquitin binding with loss of catalysis, giving
      a >100-fold reduction in enzymatic efficiency and establishing a broad requirement
      for UCHL1 in maintaining the nervous system.
    supporting_text: "resulted in a >100-fold reduction in the efficiency of UCHL1(GLU7ALA) relative "
- reference: PMID:28007905
  title: Novel UCHL1 mutations reveal new insights into ubiquitin processing.
- reference: PMID:29735986
  title: Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.
- reference: PMID:32656641
  title: Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.
- reference: PMID:12913066
  title: Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
- reference: PMID:10471497
  title: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.
- reference: PMID:11555633
  title: Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.
- reference: PMID:38185323
  title: Altered Protein Dynamics and a More Reactive Catalytic Cysteine in a Neurodegeneration-associated UCHL1 Mutant.
- reference: PMID:35986737
  title: Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.
- reference: PMID:39030458
  title: "Phenotypic variability related to dominant UCHL1 mutations: about three families with optic atrophy and ataxia."
- reference: PMID:41402561
  title: A new variant in the UCHL1 gene supporting its implication in late-onset ataxia with optic atrophy.
- reference: PMID:42375238
  title: "UCHL1-Related Dominant Optic Atrophy: Report of Two New Families."
- reference: PMID:27515257
  title: "Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction."
- reference: PMID:33159930
  title: Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.
- reference: PMID:35163618
  title: "Hereditary Spastic Paraplegia: An Update."
- reference: PMID:20301682
  title: Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview.
  tags:
  - GeneReviews
  findings:
  - statement: >-
      Recorded as the nearest GeneReviews anchor for this disease, since no GeneReviews
      chapter exists for UCHL1 or SPG79. SCOPE CAVEAT: this chapter covers *uncomplicated
      (pure)* hereditary spastic paraplegia, whereas SPG79B is a complicated HSP with
      optic atrophy, ataxia and neuropathy. Its clinical-characteristics content
      therefore does NOT describe this disease, and no evidence item in this entry draws
      a clinical claim from it. It is listed only because it is the class-level
      GeneReviews resource a curator or clinician would reach for, and because its stated
      scope includes reviewing the differential diagnosis of pure HSP with a focus on
      treatable genetic disorders.
    supporting_text: "Review the differential diagnosis of uncomplicated hereditary spastic paraplegia, which includes complicated hereditary spastic paraplegia with a focus on treatable genetic disorders"

📚

References & Deep Research

References

16

PMID:23359680

Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.

2 findings

The index report defines the entity: three siblings of a consanguineous union with childhood-onset blindness, cerebellar ataxia, nystagmus, dorsal column dysfunction and spasticity with upper motor neuron dysfunction, homozygous for UCHL1 p.Glu7Ala.

"progressive neurodegenerative syndrome featuring childhood onset blindness, "

The disease allele combines loss of ubiquitin binding with loss of catalysis, giving a >100-fold reduction in enzymatic efficiency and establishing a broad requirement for UCHL1 in maintaining the nervous system.

"resulted in a >100-fold reduction in the efficiency of UCHL1(GLU7ALA) relative "

PMID:28007905

Novel UCHL1 mutations reveal new insights into ubiquitin processing.

No top-level findings curated for this source.

PMID:29735986

Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.

No top-level findings curated for this source.

PMID:32656641

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.

No top-level findings curated for this source.

PMID:12913066

Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.

No top-level findings curated for this source.

PMID:10471497

Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice.

No top-level findings curated for this source.

PMID:11555633

Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.

No top-level findings curated for this source.

PMID:38185323

Altered Protein Dynamics and a More Reactive Catalytic Cysteine in a Neurodegeneration-associated UCHL1 Mutant.

No top-level findings curated for this source.

PMID:35986737

Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.

No top-level findings curated for this source.

PMID:39030458

Phenotypic variability related to dominant UCHL1 mutations: about three families with optic atrophy and ataxia.

No top-level findings curated for this source.

PMID:41402561

A new variant in the UCHL1 gene supporting its implication in late-onset ataxia with optic atrophy.

No top-level findings curated for this source.

PMID:42375238

UCHL1-Related Dominant Optic Atrophy: Report of Two New Families.

No top-level findings curated for this source.

PMID:27515257

Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction.

No top-level findings curated for this source.

PMID:33159930

Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.

No top-level findings curated for this source.

PMID:35163618

Hereditary Spastic Paraplegia: An Update.

No top-level findings curated for this source.

PMID:20301682

Uncomplicated (Pure) Hereditary Spastic Paraplegia Overview.

1 finding

Recorded as the nearest GeneReviews anchor for this disease, since no GeneReviews chapter exists for UCHL1 or SPG79. SCOPE CAVEAT: this chapter covers *uncomplicated (pure)* hereditary spastic paraplegia, whereas SPG79B is a complicated HSP with optic atrophy, ataxia and neuropathy. Its clinical-characteristics content therefore does NOT describe this disease, and no evidence item in this entry draws a clinical claim from it. It is listed only because it is the class-level GeneReviews resource a curator or clinician would reach for, and because its stated scope includes reviewing the differential diagnosis of pure HSP with a focus on treatable genetic disorders.

"Review the differential diagnosis of uncomplicated hereditary spastic paraplegia, which includes complicated hereditary spastic paraplegia with a focus on treatable genetic disorders"

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 33 citations 2026-08-01T18:42:15.477481

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia

Executive summary

UCHL1-related neurodegeneration is an exceptionally rare Mendelian neurodegenerative spectrum caused by impaired UCHL1, a neuron-enriched ubiquitin-processing enzyme essential for long-term axonal integrity. The historically recognized disorder is biallelic, early-onset SPG79, characterized by progressive optic atrophy/blindness, cerebellar ataxia, spasticity, and peripheral neuropathy. A pivotal 2023 Genetics in Medicine study expanded the spectrum to heterozygous loss-of-function variants producing dominantly inherited spasticity, ataxia, neuropathy, and optic atrophy. Current databases therefore separate an early-onset recessive syndrome from dominant SPG79A, although these are best understood as an allelic UCHL1 loss-of-function spectrum. Open Targets recognizes both MONDO:0014209 and MONDO:0859363 and links them specifically to UCHL1 (ENSG00000154277). (genc2019complexityofgenerating pages 23-25, OpenTargets Search: -UCHL1)

The evidence base remains small: individual families, a limited multicenter case series, and animal or cellular experiments dominate. There are no reliable prevalence, penetrance, survival, quality-of-life, biomarker, or treatment-response estimates and no identified disease-specific interventional trial. Consequently, apparent phenotype frequencies must not be interpreted as population estimates.

Row	Compact knowledge-base content	Evidence
Disease identifiers / names	Primary disease concept: UCHL1-related neurodegeneration with optic atrophy and spastic paraplegia; related indexed entities: MONDO:0014209 early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome; MONDO:0859363 spastic paraplegia 79A, autosomal dominant, with ataxia; Orphanet:352654 Early-onset progressive neurodegeneration - blindness - ataxia - spasticity; also placed within spastic paraplegia / SPG79 disease space. Information is derived mainly from aggregated disease resources plus very small published case series/families.	(OpenTargets Search: -UCHL1, bishop2016ubiquitincterminalhydrolase pages 5-6, genc2019complexityofgenerating pages 23-25)
Gene / protein	Gene: UCHL1; Ensembl: ENSG00000154277; Protein: ubiquitin C-terminal hydrolase L1 (UCH-L1), a neuron-enriched deubiquitinase/ubiquitin-processing enzyme that is highly abundant in brain and required for axonal integrity maintenance. Suggested ontology: GO deubiquitination / ubiquitin-dependent protein catabolic process.	(OpenTargets Search: -UCHL1, bishop2016ubiquitincterminalhydrolase pages 6-7, ristic2014anoptimalubiquitinproteasome pages 6-7)
Inheritance / allelic spectrum	Established recessive disease: biallelic loss-of-function/function-impairing UCHL1 variants causing early-onset progressive neurodegeneration with blindness/optic atrophy, ataxia, and spasticity; includes autosomal recessive SPG79 reports. Expanded dominant spectrum: 2023 report established heterozygous loss-of-function variants causing a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy, consistent with dominant/haploinsufficient disease concept indexed as MONDO:0859363.	(genc2019complexityofgenerating pages 23-25, bishop2016ubiquitincterminalhydrolase pages 5-6, OpenTargets Search: -UCHL1)
Core phenotypes with suggested HPO terms	Motor system: spastic paraplegia/spasticity (suggested HPO: Spastic paraplegia, Spasticity, Hyperreflexia, Extensor plantar response); cerebellar: ataxia/gait ataxia (suggested HPO: Cerebellar ataxia, Gait ataxia); optic/visual: optic atrophy, progressive visual loss/blindness (suggested HPO: Optic atrophy, Decreased visual acuity, Blindness); peripheral nerve: sensory-motor or motor axonal neuropathy (suggested HPO: Peripheral neuropathy, Axonal neuropathy); other reported in expanded spectrum: upper motor neuron degeneration, neuromuscular junction denervation. Frequencies are not well defined because published human cohorts are extremely small.	(genc2019complexityofgenerating pages 23-25, bishop2016ubiquitincterminalhydrolase pages 5-6, genc2019complexityofgenerating pages 9-11, OpenTargets Search: -UCHL1)
Key pathogenic variants / reports	p.Glu7Ala (E7A): human missense variant with severely impaired ubiquitin hydrolysis; associated with early-onset neurodegeneration, blindness around childhood, and progressive ataxia/spasticity. Novel splice-site variant in AR SPG79: reported in an Indian family with autosomal recessive spastic paraplegia-79. Heterozygous loss-of-function variants (2023 spectrum paper): multiple LoF alleles causing dominant disorder with spasticity, ataxia, neuropathy, optic atrophy. Variant-level ACMG assertions and population frequencies should be checked in ClinVar/gnomAD per allele; not fully extractable from current evidence set.	(bishop2016ubiquitincterminalhydrolase pages 5-6, genc2019complexityofgenerating pages 23-25, OpenTargets Search: -UCHL1)
Mechanism with suggested GO terms	Upstream defect: impaired UCHL1 function disrupts ubiquitin recycling and neuronal proteostasis, reducing free monoubiquitin (mouse data ~30% reduction in UCHL1-deficient strains). Cellular consequences: accumulation of polyubiquitinated proteins, proteasomal stress/impairment, compensatory autophagy changes, increased ER stress, altered mTOR balance, synaptic vesicle/NMJ degeneration, axonal transport failure, and length-dependent axon degeneration. Suggested GO terms: ubiquitin-dependent protein catabolic process; protein deubiquitination; proteasome-mediated ubiquitin-dependent protein catabolic process; response to endoplasmic reticulum stress; regulation of TOR signaling; axon development/maintenance; synapse organization; neuromuscular junction development; autophagy.	(bishop2016ubiquitincterminalhydrolase pages 6-7, mi2021abolishinguchl1shydrolase pages 8-9, bishop2016ubiquitincterminalhydrolase pages 9-10, genc2019complexityofgenerating pages 6-9, bishop2016ubiquitincterminalhydrolase pages 8-8)
Anatomy / cell types with suggested UBERON / CL terms	Primary systems: central and peripheral nervous systems. Anatomical sites: optic nerve/retinal ganglion cell pathway (suggested UBERON: optic nerve, retina), corticospinal tract / motor cortex / spinal cord, peripheral axons, neuromuscular junction. Cell types: corticospinal motor neurons / upper motor neurons, spinal motor neurons, retinal ganglion cells, peripheral neurons/axons, dopaminergic neurons in fly PD models. Suggested CL terms: motor neuron, upper motor neuron, retinal ganglion cell, neuron, dopaminergic neuron. Subcellular compartments: synapse/presynaptic terminal, endoplasmic reticulum, lysosome/autophagy pathway, ubiquitin-proteasome system components.	(genc2019complexityofgenerating pages 9-11, bishop2016ubiquitincterminalhydrolase pages 6-7, tran2018drosophilaubiquitincterminal pages 1-2, genc2019complexityofgenerating pages 6-9)
Diagnostics	Current practical diagnosis: genomic testing in patients with complex HSP / optic atrophy / ataxia / neuropathy phenotype, typically via exome/genome or curated neurogenetic panels; confirmatory single-gene analysis of UCHL1 where phenotype fits. Supportive workup may include neuro-ophthalmic examination, electrophysiology for neuropathy, and MRI/neurologic exam as indicated, but no disease-specific biomarker or standardized diagnostic criteria were found. Differential diagnosis includes other complicated HSP and optic atrophy disorders (e.g., mitochondrial/AFG3L2/SPG7/MFN2-related disorders).	(rossor2024theevolvingspectrum pages 12-13, maresca2021molecularmechanismsbehind pages 24-25, genc2019complexityofgenerating pages 23-25)
Treatment status	No disease-modifying therapy established for UCHL1-related disease. No relevant disease-specific clinical trial identified in repeated registry searches. Current care is supportive and extrapolated from HSP practice: oral baclofen or tizanidine for spasticity, intrathecal baclofen in severe cases, botulinum toxin, physiotherapy/orthotics, management of bladder urgency (e.g., oxybutynin), rehabilitation, and genetic counseling. UCHL1-targeted pharmacology exists only as experimental tool biology; not a clinical therapy for this disease.	(meyyazhagan2022hereditaryspasticparaplegia pages 18-20, OpenTargets Search: -UCHL1)
Model organisms / experimental systems	gad mouse: spontaneous exon 7-8 deletion; sensory ataxia then motor ataxia, hindlimb paralysis, axonal spheroids, death by ~6 months. nm3419 mouse: spontaneous intragenic deletion; progressive corticospinal motor neuron loss, dendrite/spine pathology, ER stress, motor impairment, NMJ denervation. UCHL1 knockout mouse: progressive paralysis, presynaptic terminal degeneration, loss of synaptic vesicles, premature death. C152A knock-in: models oxidative modification biology and partial neuroprotection after injury rather than inherited SPG79 phenotype. Drosophila dUCH knockdown: dopaminergic neurodegeneration, dopamine deficiency, locomotor dysfunction; useful for oxidative-stress and screening studies but does not specifically model optic atrophy/spastic paraplegia syndrome.	(genc2019complexityofgenerating pages 9-11, bishop2016ubiquitincterminalhydrolase pages 5-6, bishop2016ubiquitincterminalhydrolase pages 6-7, tran2018drosophilaubiquitincterminal pages 10-11, tran2018drosophilaubiquitincterminal pages 2-4)
Major evidence gaps	Disease is ultra-rare with very limited human numbers; no robust prevalence/incidence, penetrance, carrier frequency, sex ratio, survival statistics, validated natural-history staging, or genotype-phenotype frequency estimates. No disease-specific fluid biomarker, no validated omics signature, no single-cell/spatial transcriptomic data, no established modifier genes, no proven environmental/protective factors, no prevention strategy beyond genetic counseling/cascade testing, and no approved targeted therapy or interventional trial. Exact ontology IDs for several phenotypes/cell types should be finalized during curation.	(OpenTargets Search: -UCHL1, genc2019complexityofgenerating pages 23-25, meyyazhagan2022hereditaryspasticparaplegia pages 18-20)

Table: This table condenses the key identifiers, genetics, phenotypes, mechanisms, diagnostics, treatments, models, and evidence gaps for UCHL1-related neurodegeneration. It is designed for direct reuse in a disease knowledge base while clearly separating established facts from current unknowns.

1. Disease information

Definition and scope

The disease is a progressive, complicated hereditary spastic paraplegia/neurodegeneration syndrome involving long central and peripheral axons, the cerebellar system, and the anterior visual pathway. Synonyms include:

Spastic paraplegia 79 / SPG79;
SPG79A, autosomal dominant, with ataxia;
early-onset progressive neurodegeneration–blindness–ataxia–spasticity syndrome;
UCHL1-related neurodegeneration;
UCHL1-related neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.

Identifiers

MONDO:0014209: early-onset progressive neurodegeneration–blindness–ataxia–spasticity syndrome.
MONDO:0859363: spastic paraplegia 79A, autosomal dominant, with ataxia.
Orphanet:352654: early-onset progressive neurodegeneration–blindness–ataxia–spasticity.
Gene: UCHL1; Ensembl ENSG00000154277; chromosome 4p13.
A dedicated, disease-specific ICD-10, ICD-11, or MeSH code was not identified. Coding generally falls under hereditary spastic paraplegia, hereditary ataxia, optic atrophy, or other specified neurodegenerative disease. Open Targets associates UCHL1 with both MONDO disease entities and cites PMIDs 23359680, 29735986, 28007905, and 35986737 among the supporting literature. (OpenTargets Search: -UCHL1)

The knowledge is primarily aggregated disease-level information derived from published individual patients and families, not longitudinal EHR cohorts or population registries.

2. Etiology

Causal factors and genetic risk

The primary cause is a germline pathogenic variant impairing UCHL1 dosage or function. The foundational recessive phenotype involved homozygous p.Glu7Ala (E7A); Glu7 is important for ubiquitin binding, and the mutant showed severely reduced ubiquitin-hydrolysis activity in vitro. A separate Indian family had a biallelic splice-site variant causing autosomal-recessive SPG79. The 2023 study established that heterozygous loss-of-function alleles can also cause disease, supporting haploinsufficiency in dominant SPG79A. (genc2019complexityofgenerating pages 23-25, bishop2016ubiquitincterminalhydrolase pages 5-6, OpenTargets Search: -UCHL1)

All established disease-causing variants are germline. No causal somatic UCHL1 mosaicism, repeat expansion, aneuploidy, or recurrent pathogenic structural rearrangement has been established. Variant classification and allele frequency should be checked individually in current ClinVar and gnomAD records; the retrieved evidence does not support assigning one frequency to the whole disorder.

The older p.Ile93Met/PARK5 literature concerns a proposed dominant parkinsonism/toxic-gain-of-function allele and should not be conflated automatically with the optic-atrophy/SPG79 loss-of-function spectrum. Experimental transgenic evidence supports toxic effects of I93M, whereas SPG79 is principally a loss-of-function disorder. (bishop2016ubiquitincterminalhydrolase pages 7-8)

Environmental, lifestyle, infectious, and protective factors

No environmental toxin, lifestyle exposure, diet, infectious agent, age/sex exposure, or gene–environment interaction has been shown to cause or materially modify human UCHL1-related SPG79. No human protective allele is established. Oxidative stress may aggravate UCHL1 dysfunction mechanistically, but this is experimental evidence—not a validated clinical risk factor. Vitamin C rescued neuronal and locomotor phenotypes in a Drosophila dUCH-knockdown model; this does not establish vitamin C as preventive or therapeutic in affected people. (bishop2016ubiquitincterminalhydrolase pages 7-8, tran2018drosophilaubiquitincterminal pages 1-2, tran2018drosophilaubiquitincterminal pages 10-11)

3. Phenotypes

The phenotype is multisystem neurologic and generally progressive. Published numbers are too small for defensible percentages.

Spastic paraplegia/pyramidal syndrome: progressive lower-limb spasticity, weakness, gait impairment, hyperreflexia, clonus, and extensor plantar responses. Suggested HPO: Spastic paraplegia, Spasticity, Lower-limb hyperreflexia, Babinski sign, Abnormal gait.
Cerebellar dysfunction: gait and limb ataxia and sometimes dysarthria. Suggested HPO: Cerebellar ataxia, Gait ataxia, Dysmetria, Dysarthria.
Optic neuropathy: bilateral optic atrophy with progressive visual-acuity loss, potentially severe childhood blindness in recessive disease. The p.Glu7Ala report included blindness at approximately age five. Suggested HPO: Optic atrophy, Decreased visual acuity, Progressive visual loss, Blindness. (bishop2016ubiquitincterminalhydrolase pages 5-6)
Peripheral neuropathy: motor or sensorimotor, generally axonal, adding distal weakness, wasting, sensory loss, and areflexia to the upper-motor-neuron syndrome. Suggested HPO: Peripheral axonal neuropathy, Motor neuropathy, Sensory impairment. (genc2019complexityofgenerating pages 23-25)
Motor-system degeneration: experimental models demonstrate corticospinal motor-neuron loss, spinal motor-neuron involvement, distal motor-axon degeneration, and neuromuscular-junction denervation. These provide mechanistic support but should not be coded as universal human findings. (genc2019complexityofgenerating pages 9-11, bishop2016ubiquitincterminalhydrolase pages 6-7)

Onset ranges from childhood in severe biallelic disease to later-onset presentations among heterozygous loss-of-function carriers. Severity and organ involvement are variable. The course is chronic and progressive rather than episodic or relapsing. Visual loss and impaired ambulation substantially compromise education, independence, mobility, fall risk, and activities of daily living, but no UCHL1-specific EQ-5D, SF-36, PROMIS, or caregiver-burden study was found.

4. Genetic and molecular information

UCHL1 encodes ubiquitin C-terminal hydrolase L1, a 223-amino-acid protein reported to constitute approximately 1–5% of total neuronal protein. It contains a cysteine-protease catalytic triad and a restrictive crossover loop. UCHL1 appears particularly important for processing ubiquitin precursors and maintaining free monoubiquitin, rather than broadly removing ubiquitin chains from large substrates. (bishop2016ubiquitincterminalhydrolase pages 6-7, bishop2016ubiquitincterminalhydrolase pages 7-8, puri2024functionaldynamicsof pages 6-8)

Relevant variant classes include missense variants that impair ubiquitin interaction or catalysis, splice-disrupting variants, and heterozygous truncating/loss-of-function variants. Functional interpretation should assess transcript consequence, nonsense-mediated decay, protein abundance, ubiquitin binding, hydrolase activity, and segregation. No validated modifier gene, disease-specific methylation signature, pathogenic chromosomal abnormality, or recurrent copy-number syndrome is known.

For ACMG/AMP curation, strong evidence categories may include loss-of-function in a gene for which haploinsufficiency or biallelic loss is disease-causing, segregation, extreme rarity, and functional loss. However, inheritance model matters: a variant’s interpretation must distinguish dominant SPG79A from recessive SPG79 and from proposed gain-of-function parkinsonism alleles.

5. Environmental information

No disease-specific environmental, occupational, radiation, pollution, smoking, alcohol, dietary, or infectious determinant has been demonstrated. UCHL1’s Cys152 can be modified by reactive lipid products, destabilizing the protein and promoting aggregation in experimental systems; UCHL1-deficient mice are more vulnerable to lipid peroxidation and vitamin-E deficiency. These findings make oxidative injury biologically plausible as a modifier but do not justify exposure-avoidance rules or antioxidant prescriptions beyond general health guidance. (bishop2016ubiquitincterminalhydrolase pages 7-8, bishop2016ubiquitincterminalhydrolase pages 8-8)

6. Mechanism and pathophysiology

Causal chain

Upstream genetic defect: reduced UCHL1 quantity or function.
Ubiquitin-homeostasis defect: impaired ubiquitin processing/recycling lowers free monoubiquitin; UCHL1-deficient mouse strains show an approximately 30% reduction, while acute in-vitro inhibition has produced an approximately 50% reduction. (bishop2016ubiquitincterminalhydrolase pages 6-7, genc2019complexityofgenerating pages 6-9)
Proteostasis stress: ubiquitinated proteins accumulate, proteasomal efficiency falls, lysosomal/autophagic responses change, and energy demand increases. Catalytically impaired mice accumulate polyubiquitinated proteins and induce Beclin-1, consistent with compensatory autophagy. (mi2021abolishinguchl1shydrolase pages 8-9, genc2019complexityofgenerating pages 6-9)
ER and growth-signaling dysregulation: corticospinal neurons develop ER stress, dendritic vacuolation, and spine loss; UCHL1 loss is associated experimentally with increased mTORC1 activity and disturbed mTORC1/mTORC2 balance. (genc2019complexityofgenerating pages 6-9, genc2019complexityofgenerating pages 9-11)
Synaptic and transport failure: presynaptic terminals lose vesicles, neuromuscular junctions denervate, microtubule/axonal transport becomes defective, and spheroids containing ubiquitin-positive material develop. (bishop2016ubiquitincterminalhydrolase pages 6-7, bishop2016ubiquitincterminalhydrolase pages 5-6)
Length-dependent axon degeneration: long corticospinal, sensory, peripheral motor, cerebellar, and optic pathways are selectively vulnerable, producing spasticity, neuropathy, ataxia, and optic atrophy.

Cells, pathways, and ontology suggestions

Relevant cells are upper/corticospinal motor neurons, spinal motor neurons, peripheral sensory and motor neurons, retinal ganglion cells, and their axons. Suggested CL terms: motor neuron, upper motor neuron, retinal ganglion cell, sensory neuron, and neuron. Retinal ganglion cells are the source of optic-nerve axons and are intrinsically vulnerable because of their long, energy-demanding axonal architecture, although UCHL1-specific retinal-cell mechanisms remain incompletely resolved.

Suggested GO biological processes include protein deubiquitination, ubiquitin-dependent protein catabolic process, proteasome-mediated ubiquitin-dependent protein catabolic process, maintenance of protein location, response to endoplasmic-reticulum stress, autophagy, regulation of TOR signaling, axon maintenance, axonal transport, and synapse organization. Suggested GO cellular components include cytosol, axon, presynaptic terminal, neuromuscular junction, endoplasmic reticulum, proteasome complex, and lysosome.

No disease-specific human transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or integrated multi-omic signature was found. General UCHL1 structural and chemoproteomic studies exist but are not diagnostic profiles. A 2024 structural review emphasizes that disease mutations and oxidation alter UCH-family conformational dynamics; UCHL1 has much lower generic DUB efficiency than UCHL3, reinforcing its specialized ubiquitin-processing role. (puri2024functionaldynamicsof pages 6-8)

7. Anatomical structures affected

Primary involvement is neurologic:

Motor cortex and corticospinal tract—upper-motor-neuron degeneration and spastic paraplegia;
Spinal cord and peripheral motor pathways—distal axon and neuromuscular-junction degeneration;
Peripheral nerves—axonal neuropathy;
Cerebellar pathways—ataxia;
Retina/optic nerve—presumed retinal-ganglion-cell axon loss causing bilateral optic atrophy.

Suggested UBERON annotations: brain, motor cortex, spinal cord, corticospinal tract, peripheral nerve, cerebellum, retina, and optic nerve. Visual disease is generally bilateral. No consistent non-neurologic organ phenotype is established in humans, despite UCHL1 expression or functional roles in some non-neural tissues.

8. Temporal development

Biallelic disease may begin in early childhood, with visual loss and evolving ataxic-spastic motor dysfunction; the original p.Glu7Ala syndrome included blindness at about five years. Dominant loss-of-function broadens onset into later life. The onset is generally insidious, followed by slow or variable progression. (bishop2016ubiquitincterminalhydrolase pages 5-6)

A practical—not formally validated—staging concept is:

Early: visual impairment, gait imbalance, subtle pyramidal or neuropathic signs;
Intermediate: definite spastic-ataxic gait, optic atrophy, electrophysiologic neuropathy, falls;
Advanced: severe visual disability, walking-aid or wheelchair dependence, distal weakness/wasting and contractures.

No remission pattern, acute crisis phenotype, validated progression scale, median disease duration, or intervention window has been established. Animal evidence suggests proteostasis and ER-stress abnormalities precede overt neuronal loss, making presymptomatic restoration of UCHL1 function a rational—but untested—therapeutic objective. (genc2019complexityofgenerating pages 18-20, genc2019complexityofgenerating pages 9-11)

9. Inheritance and population

Both autosomal recessive and autosomal dominant UCHL1 loss-of-function disease are recognized. Recessive recurrence risk is 25% for each pregnancy of two confirmed heterozygous carriers; dominant transmission risk is nominally 50% from an affected heterozygous parent, subject to variant-specific penetrance. Penetrance, age dependence, expressivity distributions, germline mosaicism rate, anticipation, and phenocopy rate have not been quantified.

No prevalence or incidence per 100,000, carrier frequency, founder effect, geographic concentration, ethnic enrichment, or sex ratio is known. Consanguinity can increase the probability of a recessive diagnosis but is not required. The few reports include unrelated families from different populations, so no ancestry-specific conclusion is justified. General HSP prevalence estimates—reported in reviews as roughly 0.1–9.6/100,000—must not be assigned to SPG79.

10. Diagnostics

Clinical evaluation

Suspect UCHL1 disease in a patient with otherwise unexplained combinations of progressive spasticity, ataxia, axonal neuropathy, and bilateral optic atrophy. Evaluation should document neurologic examination, gait and spasticity scales, visual acuity, color vision, visual fields, fundus examination, optical coherence tomography, and—when useful—visual evoked potentials. Nerve-conduction studies/EMG can classify peripheral neuropathy. Brain and spinal MRI are principally supportive and exclude structural, inflammatory, leukodystrophic, or mitochondrial mimics.

No diagnostic enzyme assay, blood chemistry, CSF biomarker, biopsy signature, or standardized clinical criteria have been validated. UCHL1 itself is used as a neuronal-injury biomarker in other disorders, but that does not make circulating UCHL1 a validated biomarker for inherited UCHL1 deficiency.

Genetic testing

A broad WES/WGS or ataxia–HSP–optic-atrophy panel is generally preferable because phenocopies are numerous. Analysis must include single-nucleotide and indel variants, splice effects, and exon-level CNVs; segregation and parental testing are important for determining dominant versus recessive disease. WGS may identify noncoding splice or structural variants missed by exome testing. RNA studies are appropriate for suspected splice variants, and functional protein/hydrolase assays remain research tools.

CMA and karyotyping have low expected yield for an isolated single-gene phenotype unless syndromic copy-number disease is suspected. FISH, mitochondrial-DNA testing, and repeat-expansion testing are differential-diagnosis tools, not UCHL1 assays.

Differential diagnosis

Important alternatives include SPG7, AFG3L2, OPA1, MFN2, PNPT1, FDXR, WFS1, SACS, KIF1A, CAPN1, mitochondrial disorders, Friedreich ataxia, and treatable metabolic HSPs. SPG7/AFG3L2/MFN2 disorders can combine spasticity or neuropathy with optic atrophy through mitochondrial mechanisms, whereas UCHL1 disease is primarily a neuronal ubiquitin/proteostasis disorder. (rossor2024theevolvingspectrum pages 12-13, maresca2021molecularmechanismsbehind pages 24-25)

Cascade testing is appropriate after identifying a familial pathogenic variant. Population or newborn screening is not established.

11. Outcome and prognosis

Human survival, mortality, life expectancy, and 5- or 10-year outcomes are unknown. The disorder can cause major lifelong morbidity through visual disability, progressive gait impairment, falls, neuropathic weakness, contractures, and loss of independence. No evidence supports spontaneous neurologic recovery.

Mouse null models have much more rapid courses—progressive paralysis and death at approximately 6–7 months—and should not be used to predict human life expectancy. (bishop2016ubiquitincterminalhydrolase pages 5-6, bishop2016ubiquitincterminalhydrolase pages 6-7)

No validated prognostic biomarker exists. Plausible prognostic variables include inheritance mode, residual UCHL1 function, age at onset, early visual involvement, axonal-neuropathy burden, and rate of gait decline, but none has been prospectively validated.

12. Treatment

There is no approved disease-modifying treatment, gene therapy, RNA therapy, cell therapy, or UCHL1-directed drug for SPG79. Repeated registry searches found no relevant disease-specific interventional study. Management is multidisciplinary and extrapolated from complicated HSP practice.

Spasticity: oral baclofen or tizanidine; focal botulinum toxin; intrathecal baclofen for severe generalized spasticity after specialist assessment. Suggested NCIT concepts: Baclofen, Tizanidine, Botulinum Toxin Therapy, Intrathecal Drug Administration.
Mobility: physical therapy, daily stretching, strengthening, balance work, ankle-foot orthoses, walking aids, wheelchair/seating assessment, and fall prevention. Suggested NCIT: Physical Therapy, Occupational Therapy, Rehabilitation Therapy, Orthotic Device.
Bladder dysfunction: clinical assessment and agents such as oxybutynin when indicated.
Neuropathy and complications: foot care, neuropathic-pain treatment, contracture prevention, nutrition and swallowing evaluation where clinically required.
Vision: low-vision rehabilitation, assistive technology, educational/workplace adaptation, and ophthalmologic surveillance.
Genetic care: counseling, cascade testing, and reproductive options.

General HSP literature reports oral baclofen/tizanidine, intrathecal baclofen, botulinum toxin plus stretching, orthotics, peroneal stimulation, exercise, and bladder treatment, but no UCHL1-specific response rate or adverse-event estimate exists. (meyyazhagan2022hereditaryspasticparaplegia pages 18-20)

Experimental concepts include restoring UCHL1 expression, preserving monoubiquitin, correcting proteostasis/ER stress, or preventing oxidative inactivation. UCHL1 inhibition would be mechanistically counterintuitive for loss-of-function disease. AAV-mediated UCHL1 overexpression has benefited Alzheimer-model mice, and vitamin C rescued a fly-knockdown phenotype, but neither constitutes SPG79 efficacy evidence. (tran2018drosophilaubiquitincterminal pages 1-2, tran2018drosophilaubiquitincterminal pages 10-11)

13. Prevention

Primary lifestyle prevention is not possible for a germline Mendelian disorder. No vaccine, medication, dietary supplement, or exposure intervention prevents disease.

Secondary prevention consists of familial variant identification, cascade testing, early neuro-ophthalmic and motor assessment, and prompt rehabilitation. Reproductive options include prenatal diagnosis and preimplantation genetic testing after a familial pathogenic variant is established. Tertiary prevention includes maintaining range of motion, preventing falls and contractures, protecting insensate feet, managing bladder complications, and providing low-vision and mobility support. Genetic counseling must explicitly address whether the family has dominant or recessive UCHL1 disease.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart or zoonotic form was identified. The condition is not infectious and has no zoonotic potential. UCHL1 is evolutionarily conserved; Drosophila dUCH shares approximately 43.7% sequence identity with mammalian UCHL1 and preserves catalytic features. (tran2018drosophilaubiquitincterminal pages 2-4)

Suggested taxa for experimental annotations are Mus musculus (NCBI Taxon 10090) and Drosophila melanogaster (NCBI Taxon 7227). No breed-specific VBO annotation is applicable.

15. Model organisms

Mouse

gad mouse: spontaneous in-frame deletion of Uchl1 exons 7–8. Sensory ataxia appears around three months, motor ataxia around four months, followed by paralysis and death near six months. Axonal spheroids, ubiquitin-positive deposits, transport failure, and Wallerian degeneration are prominent and increase with axon length. (bishop2016ubiquitincterminalhydrolase pages 5-6)
Uchl1nm3419: intragenic deletion involving exons 6–8. It reproduces motor impairment, progressive corticospinal-neuron loss, vacuolated apical dendrites, spine loss, ER stress, spinal-motor-neuron involvement, and NMJ denervation. (genc2019complexityofgenerating pages 9-11)
Targeted Uchl1 knockout: progressive ataxia/paralysis, axon degeneration, presynaptic-terminal degeneration, loss of synaptic vesicles, and premature death. (bishop2016ubiquitincterminalhydrolase pages 6-7)
Catalytic C90A and oxidative-site C152A knock-ins: dissect hydrolase and oxidative-injury functions. C90A worsens axonal and neuronal injury after trauma but does not reproduce the full null phenotype, indicating important non-hydrolase functions. (mi2021abolishinguchl1shydrolase pages 8-9)

A key limitation is that optic atrophy has not been consistently reproduced or systematically evaluated in all Uchl1-deficient mouse lines. Their rapid severe course also differs from many human heterozygous cases.

Drosophila

TH-GAL4-driven dUCH RNAi causes progressive degeneration of defined dopaminergic-neuron clusters, chronic dopamine deficiency, and locomotor dysfunction. Vitamin C at 0.5 mM rescued neuron loss and locomotor impairment. This is useful for high-throughput neuroprotection and oxidative-stress studies but models dopaminergic degeneration rather than the complete human optic-atrophy/spastic-ataxia syndrome. (tran2018drosophilaubiquitincterminal pages 10-11, tran2018drosophilaubiquitincterminal pages 2-4)

Cellular systems

Patient-derived neuronal models remain underdeveloped. Existing primary-neuron, injury, glioblastoma, and other cell assays establish effects on ubiquitin abundance, proteostasis, oxidative injury, and aggregation but are not faithful disease-specific models. Patient iPSC-derived corticospinal motor neurons and retinal ganglion cells, organoids, and isogenic CRISPR-corrected lines are high-priority future resources.

Recent developments and expert assessment

The most important recent development is the 2023 expansion from a purely recessive childhood syndrome to heterozygous loss-of-function disease, changing genetic counseling and variant interpretation. The paper’s title summarizes its principal conclusion: “Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy” (Genetics in Medicine, October 2023; DOI: https://doi.org/10.1016/j.gim.2023.100961). Open Targets now indexes the dominant entity separately as MONDO:0859363. (OpenTargets Search: -UCHL1)

Recent 2024 reviews place UCHL1 among genes crossing traditional boundaries between hereditary neuropathy, spastic paraplegia, and cerebellar ataxia. This is clinically appropriate: diagnostic classification by the leading symptom alone risks missing the multisystem syndrome. The authoritative mechanistic view remains that UCHL1 is “absolutely required for the maintenance of axonal integrity,” while its complete substrate repertoire and the cause of selective neuronal vulnerability remain unresolved. (bishop2016ubiquitincterminalhydrolase pages 6-7, bishop2016ubiquitincterminalhydrolase pages 8-8)

Evidence gaps and curation cautions

Do not merge dominant SPG79A, recessive SPG79, and PARK5 without preserving inheritance and molecular-mechanism qualifiers.
Do not infer phenotype percentages from a handful of reported families.
No reliable prevalence, incidence, penetrance, sex ratio, survival, natural-history scale, or quality-of-life statistic exists.
No validated human biomarker, disease-specific omics profile, protective factor, modifier gene, or targeted treatment exists.
Model-organism rescue by antioxidants or UCHL1 expression is hypothesis-generating only.
Variant-level ClinVar, gnomAD, transcript, HGVS, and ACMG assertions should be refreshed at the time of database ingestion.

Key literature links

Foundational human recessive disease: PMID 23359680; PNAS (2013), “Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.”
Indian AR SPG79 splice variant: PMID 29735986; Journal of Human Genetics (2018), DOI: https://doi.org/10.1038/s10038-018-0463-6.
Dominant loss-of-function spectrum: Genetics in Medicine (October 2023), DOI: https://doi.org/10.1016/j.gim.2023.100961.
UCHL1 structure/function review: Biochemical Journal (August 2016), DOI: https://doi.org/10.1042/BCJ20160082. (bishop2016ubiquitincterminalhydrolase pages 6-7)
Mouse upper-motor-neuron models: International Journal of Molecular Sciences (August 2019), DOI: https://doi.org/10.3390/ijms20163848. (genc2019complexityofgenerating pages 18-20, genc2019complexityofgenerating pages 9-11)
Drosophila dUCH knockdown: Scientific Reports (March 2018), DOI: https://doi.org/10.1038/s41598-018-22804-w. (tran2018drosophilaubiquitincterminal pages 1-2, tran2018drosophilaubiquitincterminal pages 10-11)
General HSP management review: International Journal of Molecular Sciences (February 2022), DOI: https://doi.org/10.3390/ijms23031697. (meyyazhagan2022hereditaryspasticparaplegia pages 18-20)

References

(genc2019complexityofgenerating pages 23-25): Baris Genc, Oge Gozutok, and P. Hande Ozdinler. Complexity of generating mouse models to study the upper motor neurons: let us shift focus from mice to neurons. International Journal of Molecular Sciences, 20:3848, Aug 2019. URL: https://doi.org/10.3390/ijms20163848, doi:10.3390/ijms20163848. This article has 37 citations.
(OpenTargets Search: -UCHL1): Open Targets Query (-UCHL1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(bishop2016ubiquitincterminalhydrolase pages 5-6): Paul Bishop, Dan Rocca, and Jeremy M. Henley. Ubiquitin c-terminal hydrolase l1 (uch-l1): structure, distribution and roles in brain function and dysfunction. Biochemical Journal, 473:2453-2462, Aug 2016. URL: https://doi.org/10.1042/bcj20160082, doi:10.1042/bcj20160082. This article has 389 citations and is from a domain leading peer-reviewed journal.
(bishop2016ubiquitincterminalhydrolase pages 6-7): Paul Bishop, Dan Rocca, and Jeremy M. Henley. Ubiquitin c-terminal hydrolase l1 (uch-l1): structure, distribution and roles in brain function and dysfunction. Biochemical Journal, 473:2453-2462, Aug 2016. URL: https://doi.org/10.1042/bcj20160082, doi:10.1042/bcj20160082. This article has 389 citations and is from a domain leading peer-reviewed journal.
(ristic2014anoptimalubiquitinproteasome pages 6-7): Gorica Ristic, Wei-Ling Tsou, and Sokol V. Todi. An optimal ubiquitin-proteasome pathway in the nervous system: the role of deubiquitinating enzymes. Frontiers in Molecular Neuroscience, Aug 2014. URL: https://doi.org/10.3389/fnmol.2014.00072, doi:10.3389/fnmol.2014.00072. This article has 107 citations.
(genc2019complexityofgenerating pages 9-11): Baris Genc, Oge Gozutok, and P. Hande Ozdinler. Complexity of generating mouse models to study the upper motor neurons: let us shift focus from mice to neurons. International Journal of Molecular Sciences, 20:3848, Aug 2019. URL: https://doi.org/10.3390/ijms20163848, doi:10.3390/ijms20163848. This article has 37 citations.
(mi2021abolishinguchl1shydrolase pages 8-9): Zhiping Mi, Hao Liu, Marie E. Rose, Xiecheng Ma, Daniel P. Reay, Jie Ma, Jeremy Henchir, C. Edward Dixon, and Steven H. Graham. Abolishing uchl1's hydrolase activity exacerbates tbi-induced axonal injury and neuronal death in mice. Feb 2021. URL: https://doi.org/10.1016/j.expneurol.2020.113524, doi:10.1016/j.expneurol.2020.113524. This article has 27 citations and is from a peer-reviewed journal.
(bishop2016ubiquitincterminalhydrolase pages 9-10): Paul Bishop, Dan Rocca, and Jeremy M. Henley. Ubiquitin c-terminal hydrolase l1 (uch-l1): structure, distribution and roles in brain function and dysfunction. Biochemical Journal, 473:2453-2462, Aug 2016. URL: https://doi.org/10.1042/bcj20160082, doi:10.1042/bcj20160082. This article has 389 citations and is from a domain leading peer-reviewed journal.
(genc2019complexityofgenerating pages 6-9): Baris Genc, Oge Gozutok, and P. Hande Ozdinler. Complexity of generating mouse models to study the upper motor neurons: let us shift focus from mice to neurons. International Journal of Molecular Sciences, 20:3848, Aug 2019. URL: https://doi.org/10.3390/ijms20163848, doi:10.3390/ijms20163848. This article has 37 citations.
(bishop2016ubiquitincterminalhydrolase pages 8-8): Paul Bishop, Dan Rocca, and Jeremy M. Henley. Ubiquitin c-terminal hydrolase l1 (uch-l1): structure, distribution and roles in brain function and dysfunction. Biochemical Journal, 473:2453-2462, Aug 2016. URL: https://doi.org/10.1042/bcj20160082, doi:10.1042/bcj20160082. This article has 389 citations and is from a domain leading peer-reviewed journal.
(tran2018drosophilaubiquitincterminal pages 1-2): Hiep H. Tran, Suong N. A. Dang, Thanh T. Nguyen, Anh M. Huynh, Linh. M. Dao, Kaeko Kamei, Masamitsu Yamaguchi, and Thao T. P. Dang. Drosophila ubiquitin c-terminal hydrolase knockdown model of parkinson’s disease. Scientific Reports, Mar 2018. URL: https://doi.org/10.1038/s41598-018-22804-w, doi:10.1038/s41598-018-22804-w. This article has 34 citations and is from a peer-reviewed journal.
(rossor2024theevolvingspectrum pages 12-13): Alexander M. Rossor, Saif Haddad, and Mary M. Reilly. The evolving spectrum of complex inherited neuropathies. Current Opinion in Neurology, 37:427-444, Jul 2024. URL: https://doi.org/10.1097/wco.0000000000001307, doi:10.1097/wco.0000000000001307. This article has 12 citations and is from a peer-reviewed journal.
(maresca2021molecularmechanismsbehind pages 24-25): Alessandra Maresca and Valerio Carelli. Molecular mechanisms behind inherited neurodegeneration of the optic nerve. Biomolecules, 11:496, Mar 2021. URL: https://doi.org/10.3390/biom11040496, doi:10.3390/biom11040496. This article has 21 citations.
(meyyazhagan2022hereditaryspasticparaplegia pages 18-20): Arun Meyyazhagan and Antonio Orlacchio. Hereditary spastic paraplegia: an update. International Journal of Molecular Sciences, 23:1697, Feb 2022. URL: https://doi.org/10.3390/ijms23031697, doi:10.3390/ijms23031697. This article has 197 citations.
(tran2018drosophilaubiquitincterminal pages 10-11): Hiep H. Tran, Suong N. A. Dang, Thanh T. Nguyen, Anh M. Huynh, Linh. M. Dao, Kaeko Kamei, Masamitsu Yamaguchi, and Thao T. P. Dang. Drosophila ubiquitin c-terminal hydrolase knockdown model of parkinson’s disease. Scientific Reports, Mar 2018. URL: https://doi.org/10.1038/s41598-018-22804-w, doi:10.1038/s41598-018-22804-w. This article has 34 citations and is from a peer-reviewed journal.
(tran2018drosophilaubiquitincterminal pages 2-4): Hiep H. Tran, Suong N. A. Dang, Thanh T. Nguyen, Anh M. Huynh, Linh. M. Dao, Kaeko Kamei, Masamitsu Yamaguchi, and Thao T. P. Dang. Drosophila ubiquitin c-terminal hydrolase knockdown model of parkinson’s disease. Scientific Reports, Mar 2018. URL: https://doi.org/10.1038/s41598-018-22804-w, doi:10.1038/s41598-018-22804-w. This article has 34 citations and is from a peer-reviewed journal.
(bishop2016ubiquitincterminalhydrolase pages 7-8): Paul Bishop, Dan Rocca, and Jeremy M. Henley. Ubiquitin c-terminal hydrolase l1 (uch-l1): structure, distribution and roles in brain function and dysfunction. Biochemical Journal, 473:2453-2462, Aug 2016. URL: https://doi.org/10.1042/bcj20160082, doi:10.1042/bcj20160082. This article has 389 citations and is from a domain leading peer-reviewed journal.
(puri2024functionaldynamicsof pages 6-8): Sarita Puri and Shang-Te Danny Hsu. Functional dynamics of human ubiquitin c-terminal hydrolases. Frontiers in Biophysics, Nov 2024. URL: https://doi.org/10.3389/frbis.2024.1479898, doi:10.3389/frbis.2024.1479898. This article has 5 citations.
(genc2019complexityofgenerating pages 18-20): Baris Genc, Oge Gozutok, and P. Hande Ozdinler. Complexity of generating mouse models to study the upper motor neurons: let us shift focus from mice to neurons. International Journal of Molecular Sciences, 20:3848, Aug 2019. URL: https://doi.org/10.3390/ijms20163848, doi:10.3390/ijms20163848. This article has 37 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Variants

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

UCHL1-Related Neurodegeneration with Optic Atrophy and Spastic Paraplegia

Executive summary

1. Disease information

Definition and scope

Identifiers

2. Etiology

Causal factors and genetic risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

Cells, pathways, and ontology suggestions

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical evaluation

Genetic testing

Differential diagnosis

11. Outcome and prognosis

12. Treatment

13. Prevention

14. Other species and natural disease

15. Model organisms

Mouse

Drosophila

Cellular systems

Recent developments and expert assessment

Evidence gaps and curation cautions

Key literature links

Artifacts